 
 
PREVENTION OF URINARY STONES WITH H YDRATION 
(PUSH) 
A randomized clinical trial to investigate the impact of increased fluid 
intake and increased urine output on the recurrence rate of urinary stone 
disease (USD) in adults and children  
 STUDY PROTOCOL   
Protocol Identifying Number: USDRN01  
Principal Investigator (s):  Charles D. Scales, Jr., MD MSHS 
    Hussein  R. Al-Khalidi, PhD  
Funded by : National Institute of Diabetes and Digestive and Kidney Diseases  
(NIDDK)  
Version Number:  5 .0  
Date:  February 4, 2020  
 
[STUDY_ID_REMOVED]  
 

ii 
 Table of Contents  
LIST OF ABBREVIATIONS  .................................................................................................................................. 1 
STATEMENT OF COMPLIANCE  ......................................................................................................................... 2 
PROTOCOL SUMMARY ....................................................................................................................................... 3 
SCHEMATIC OF STUDY  DESIGN  ...................................................................................................................... 4 
1 KEY ROLES  ............................................................................................................................................... 4 
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ....................... 5 
2.1 Background Information  ................................................................................................................. 5 
2.2 Rationale .......................................................................................................................................... 5 
2.3 Potential Risks and Benefits  .......................................................................................................... 6 
2.3.1  Known Potential Risks  .................................................................................................  6 
2.3.2  Known Potential Benefits ............................................................................................. 6 
3 OBJECTIVES AND PURPOSE  ................................................................................................................ 7 
4 STUDY DESIGN AND ENDPOINTS  ....................................................................................................... 8 
4.1 Description of the Study Design  .................................................................................................... 8 
4.2 Study Endpoints  .............................................................................................................................. 9 
4.2.1  Primary Endpoint  .......................................................................................................... 9 
4.2.2  Secondary Endpoints  ................................................................................................... 9 
4.2.3  Exploratory Endpoints  .................................................................................................. 9 
4.3 Randomization  .................................................................................................................................  9 
4.4 Requirement for Low Urine Volume  ............................................................................................ 10 
5 STUDY ENROLLMENT AND WITHDRAWAL  ...................................................................................... 10 
5.1 Participant Inclusion Criteria  ........................................................................................................ 10 
5.2 Participant Exclusion Criteria  ....................................................................................................... 10 
5.3 Strategies for Recruitment and Retention  ................................................................................... 12 
5.4 Participant Withdrawal or termination  ......................................................................................... 13 
5.4.1  Reasons for Withdrawal or Termination  ................................................................... 13 
5.4.2  Handling of Participant Withdrawals or Termination  ............................................... 13 
6 STUDY INTERVENTION  ........................................................................................................................ 13 
6.1 Study Interventions and Control Description  .............................................................................. 13 
6.1.1  Overview  ..................................................................................................................... 13 
6.1.2  Financial Incentives .................................................................................................... 15 
6.1.3  Structured Problem Solving  ...................................................................................... 16 
6.2 Structured Problem Solving Fidelity Procedures  ....................................................................... 17 
7 STUDY PROCEDURES AND SCHEDULE  .......................................................................................... 18 
7.1 Study Procedures/Evaluations  ..................................................................................................... 18 
7.1.1  Study -Specific Procedures  ........................................................................................ 18 
7.1.3  Standard of Care Study Procedures  ........................................................................ 21 
7.1.4  Biorepository Specimen Collection  ........................................................................... 22 
7.1.5  Data Collection Process  ............................................................................................ 22 
7.2 Laboratory Procedures/Evaluations  ............................................................................................ 23 
7.2.1  Clinical Laboratory Evaluations ................................................................................. 23 
7.2.2  Other Assays or Procedures  ..................................................................................... 23 
7.2.3  Specimen Preparation, Handling, and Storage  ....................................................... 23 
7.2.4  Specimen Shipment  ................................................................................................... 23 
7.3 Schedule of Events Table  ......................................................................................... 24 
iii 
 7.4 Concomitant Medications, Treatments, and Procedures  .......................................................... 26 
7.4.1. Changes in Participant Clinical Status or Treatment During the Trial  .......................................... 26 
7.5 Prohibited Medications, Treatments, and Procedures ............................................................... 27 
8 ASSESSMENT OF SAFETY .................................................................................................................. 27 
8.1 Specification of Safety Parameters  ............................................................................................. 27 
8.1.1  Definition of Adverse Events (AE)  ............................................................................ 27 
8.1.2  Definition of Serious Adverse Events (SAE) ............................................................ 27 
8.1.3  Definition of Unanticipated Problems (UP)  .............................................................. 28 
8.2 Classification of an Adverse Event  .............................................................................................. 28 
8.2.1  Assessment Of Adverse Event Severity  .................................................................. 28 
8.2.3  Expectedness  ............................................................................................................. 29 
8.3 Time Period and Frequency for Event Assessment and Follow -Up......................................... 29 
8.4 Reporting Procedures  ................................................................................................................... 29 
8.4.1  Adverse Event Reporting ........................................................................................... 29 
8.4.2   Serious Adverse Events  .................................................................................................................. 29 
8.4.3 Serious Adverse Event Reporting  ............................................................................ 29 
8.4.4  Unanticipated Problem Reporting  ............................................................................. 30 
8.4.5  Events of Special Interest  .......................................................................................... 30 
8.4.6  Reporting of Pregnancy  ............................................................................................. 30 
8.5 Safety Oversight  ............................................................................................................................ 30 
9 CLINICAL MONITORING ....................................................................................................................... 31 
10 STATISTICAL CONSIDERATIONS  ....................................................................................................... 31 
10.1  Statistical and Analytical Plans  .................................................................................................... 31 
10.2  Statistical Hypotheses  .................................................................................................................. 32 
10.3  Analysis Datasets  .......................................................................................................................... 32 
10.4  Description of Statistical Methods  ............................................................................................... 32 
10.4.1  General Approach  ...................................................................................................... 32 
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  ........................................................... 32 
10.4.3  Analysis of the Secondary Endpoint(s)  .................................................................... 33 
10.4.4  Safety Analyses  .......................................................................................................... 33 
10.4.5  Adherence and Retention Analyses  ......................................................................... 33 
10.4.6  Baseline Descriptive Statistics  .................................................................................. 33 
10.4.7  Planned Interim Analyses  .......................................................................................... 33 
10.4.9  Multiple Comparison/Multiplicity  ............................................................................... 34 
10.4.10 Economic Analysis  34 
10.5  Sample Size  ................................................................................................................................... 35 
10.6  Measures to Minimize Bias  .......................................................................................................... 36 
10.6.1  Enrollment/ Randomization/ Masking Procedures  .................................................. 36 
10.6.2  Evaluation of Success of Blinding  ............................................................................ 36 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  .................................  36 
12 QUALITY ASSURANCE AND QUALITY CONTROL  ........................................................................... 37 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS ................................................................................ 37 
13.1  Ethical Standard  ............................................................................................................................ 37 
13.2  Institutional Review Board  ............................................................................................................ 38 
13.3  Informed Consent Process  ........................................................................................................... 38 
13.3.1  Consent Procedures and Documentation  ................................................................ 38 
iv 
 13.4  Participant and Data Confidentiality  ............................................................................................ 39 
13.4.1  Research Use of Stored Human Samples, Specimens or Data  ............................ 41 
13.5  Future Use of Stored Specimens .................................................................................................  41 
14 DATA HANDLING AND RECORD KEEPING  ...................................................................................... 41 
14.1  Data Collection and Management Responsibilities  ................................................................... 41 
14.2  Study Records Retention .............................................................................................................. 42 
14.3  Protocol Deviations  ....................................................................................................................... 42 
14.4  Publication and Data Sharing Policy  ........................................................................................... 43 
15 CONFLICT OF INTEREST POLICY  ...................................................................................................... 43 
16  LITERATURE REFERENCES  ............................................................................................................... 43 
APPENDIX  ........................................................................................................................................................... 47 
 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  1 LIST OF ABBREVIATIONS 
 
AUA  American Urological Association  
CASUS  Comprehensive Assessment of Self -reported Urinary Symptoms  
CC Clinical Center  
DSMB  Data and Safety Mointoring Board  
eCRF  Electronic Case Report Form  
EDC Electronic Data Capture  
EMR  Electronic Medical Record  
FI Financial Incentive  
GCP Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
ICF Informed Consent Form  
IRB Institutional Review Board  
LAR Legally Authorized Representative  
LUTS  Lower Urinary Tract Symptoms  
MOP  Manual of Procedures  
NIDDK  National Institute of Diabetes and Digestive and Kidney Diseases  
NIH National Institutes of Health  
PI Principal Investigator  
PUSH  Preventing Urinary Stones with Hydration  
RBM  Risk-Based Monitoring  
SPS Structured Problem Solving  
SDRC  Scientific Data Research Center  
UOP  Urine Output  
USD  Urinary Stone D isease  
USDRN  Urinary  Stone Disease Research Network  
WTH  Way to Health  
  
 
  
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  2  
STATEMENT OF COMPLIA NCE  
 
 
I have read the protocol, including all appendices, and I agree that it contains all necessary details for me 
and my staff to conduct this study as described. I will personally oversee the conduct of this study as 
outlined herein and will make a reasonable effort to complete the study within the time designated.  
 I will provide all study personnel under my supervision with copies of the protocol. I will discuss this 
material with them to ensure that they are fully informed about the efficacy and safety parameters and the conduct of the study in general. I am aware that, before beginning this study, the Institutional Review Board responsible for such ma tters must approve this protocol in the clinical facility where it will be 
conducted. I agree to make all reasonable efforts to adhere to the attached protocol.  
 I agree to provide all study participants with informed consent forms, as required by government and International Conference on Harmonization regulations. I further agree to report to the sponsor any adverse experiences in accordance with the terms of this protocol .  
  
________________________________       
Principal investigator Name (prin t)  
 
 ________________________________  
Signature  
  
 
________________________________   
Date  
   
 
             
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  3 PROTOCOL SUMMARY  
  
Protocol Number  USDRN01  
Protocol Title : Prevention of Urinary Stones with Hydration (PUSH)  
Main Criteria for Inclusion : Study participant s > 12 years of age with > 1 symptomatic stone event in 
past 3 -5 years  
Study O bjectives:  To determine whether a multi -component program of behavioral 
interventions will result in reduced risk of stone disease 
recurrence/ progression over a 2 year period.  
Study Design : Randomized, blinded, prospective clinical trial  
Intervention Regimen  Behavioral intervention program  
Duration of Study 
Participation  24 months  
Duration of Study Overall  4 years  
End-of-study Definition  Last study participant  completion of 24 -month follow -up 
Number of Study Participant s Approximately 1642 
Number of Clinical Centers : 6 
Primary Endpoint : Symptomatic stone event  
Secondary Endpoints : Asymptomatic stone recurrence  
Stone growth  
Fluid intake adherence  
Urine volume  
Cost identification  
  
 
 
   
 
       
 
  
  
 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  4  
 
SCHEMATIC OF STUDY D ESIGN  
 
1 KEY ROLES  
Charles D Scales , Jr (SDRC PI, Duke Clinical Research Institute ) 
Hussein Al- Khalidi ( SDRC Stats PI, Duke Clinical Research Institute ) 
Greg Tasian ( CC PI, Children’s Hospital of Philadelphia/University of Pennsylvania)  
Peter Reese ( CC co-PI, University of Pennsylvania)  
Naim Maalouf ( CC PI, University of Texas Southwestern Medical Center)  
Jonathan Harper ( CC PI, University of Washington)  
Hunter Wessells ( CC co-PI, University of Washington)  
Henry Lai ( CC PI, Washington University, St Louis)  
Alana Desai ( CC co-PI, Washington University, St Louis)  
John Lieske (PI, Mayo Clinic, Rochester)  
Sri Sivalingam (PI, Cleveland Clinic)  

PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  5 2  INTRODUCTION: BAC KGROUND INFORMATION AND SCIENTIFIC RATIONALE  
 
2.1 BACKGROUND INFORMATION  
Urinary stone disease (USD) in the United States is an important medical, scientific, and public health 
problem.  The prevalence of urinary stones has nearly doubled in the past 15 years1 and health care 
utilization for treating patients  with stones has risen in parallel.2,3 USD affects 1 in 11 persons in the 
United States, a prevalence sim ilar to that of diabetes.1  Estimates from the Urologic Diseases in America 
project suggest that aggregate expenditures for treating study participants  with urinary  stones exceeds 
$10 billion, making USD  one of the most expensive urologic conditions.2  
Fluid intake is an appealing intervention for the secondary preven tion of USD  because it is effective, low 
risk, and inexpensive.4-7 In a randomized trial of adults with urinary  stones, fluid intake that resulted in a 
urine output greater than 2L/day decreased stone recurrence by 55% and increased the time to 
recurrence by more than 1 year.4 Although stone formers are routinely counseled to drink more fluids , 
the average  increase in 24- hour urine volume among adults with USD  is only 300mL,8 suggesting that 
adherence to fluid intake recommendations is low even when the risks of non- compliance are severe. 
Identifying ways to change behaviors to decrease USD recurrence is an area in need of research.9  
  
2.2 RATIONALE  
Most therapies for USD are directed toward treating an acute stone episode. Review of current prevention -focused guidelines reveals substantial divergence on recommendations by different 
organizations and a surprising number of recommendations based on expert opinion. 10,11  Current 
guidelines do agree, however, on one fundamental lifestyle change for USD prevention: maintaining a high oral fluid intake  resulting in high urine output (UOP) .  Therefore, an interventional trial targeting 
adherence to high oral fluid intake offers potential for supporting novel secondary prevention strategies 
for USD patients.  
Substantial evidence exists for the efficacy of adherence interventions grounded in Contingency 
Management Theory and behavioral economics. For example, appropriately structured financial incentives  (FI) can lead to improvements in smoking cessation,
12-15 weight loss,16-19 substance abuse 
management20-22 and medication adherence.23-25  The Contingency Management perspective on 
behavior change is built upon B.F. Skinner’s26 studies of operant conditioning, which showed how many 
behaviors are acquired and reinforced by environmental contingencies. Contingency Management therefore attempts to modify behavior by changing the consequences of the behavior.
27 In a 
complementary way, behavioral economics research has examined how common decision errors contribute to health risk behaviors , such as lack of fluid intake, and suggests ways in which these 
decision -errors can also be used to structure  successful interventions to improve health. W e will apply FI 
to help maintain high fluid intake among USD study participants.  
 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  6 Other behavior change research has examined Structured Problem Solving (SPS) as a means to improve 
medication adherence and self -management.28-30 SPS addresses behavior change by: a) identifying 
personal barriers to change, b) identifying feasible solutions the patient is able to implement, and c) 
continually evaluating the efficacy of the approach.  Some  studies have examined the role of self -
monitoring, social interventions (e.g., peer feedback, team competition) and device -based reminders to 
improve adherence behaviors.  While many of these interventions have been evaluated in isolation and 
over relatively short durations (<1 year), a key unanswered question is whether these interventions can be integrated t o foster durable behavior change .  
Increasingly, researchers are conducting pragmatic, multi -component trials to improve outcomes and 
care delivery.
31-33  Therefore the proposed study will test a theory- based program of interventions 
directed towards maintaining a high fluid intake.  A key secondary goal of the proposed trial will be to add to the evidence base regarding fluid for prevention of urinary stones.  Existing guideline 
recommendations for increased fluid intake to prevent stones derive from two randomized clinical trials 
(RCT) of increased fluid intake.
4,34  One RCT demonstrated a reduced risk of stone formation (RR 0.45, 
95% CI 0.24 – 0.84) over a five year period, 4 although the trial has been rated as poor quality due to 
unclear allocation concealment, lack of blinding and use of analytic methods that did not adhere to 
intention -to-treat principles.35  The other randomized trial provided insufficient evidence regarding the 
intervention due to a low number of outcome events.35  Both trials included only adult study 
participant s, and therefore the generalizability of fluid intake for secondary stone prevention among 
children remains unclear.  Thus, an important gap in evidence exists for a key  component of guideline -
based secondary prevention.  
 
2.3 POTENTIAL RISKS AND BENEFITS  
 
2.3.1  KNOWN  POTENTIAL RISKS  
The research involves the collection of protected health data. There is a small risk of loss of 
confidentiality but the researchers have in place several mechanisms for reducing this risk as described below  (see section 13.4). There is also a potential risk of water intoxication leading to hyponatremia. 
The likelihood for this event is lo w, but theoretically possible.  The investigators will mitigate this risk by 
excluding study participants  with a prior history of hyponatremia  or diseases and conditions 
predisposing an individual to hyponatremia.  Furthermore,  study participants  will be counseled  
regarding the risk of hyponatremia from consumption of water beyond the recommended volume , as 
well as symptoms and consequences of severe hyponatremia. 
 
2.3.2  KNOWN POTENTIAL BENE FITS  
All participants in PUSH will receive educational information on the importance of fluid intake. Through participation in this study, each participant will have the potential to increase their fluid intake, which could improve their health and reduce their risk for future USD . If this approach is effective, it could 
have tremendous benefits for society if adopted on a wide scale to help individuals increase fluid intake 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  7 after experien cing a urinary stone event. It is expected that other people will gain knowledge from this 
study and that participation could help clinicians  and study participants  understand how to effectively 
motivate increased fluid intake  and reduce the risk of kidney  stones.  
 
Children and families, as well as adult participants, will have the benefit of volunteerism. The medical, physical and social risks are minimal for all participants and are small in relation to the anticipated benefits of the knowledge to be gained. Additionally, the information that is obtained will be disseminated as widely as possible, including through submission for publication in peer -reviewed 
journals, presented at  scientific conferences, and the many dissemination channels of the NIDDK and 
academic institutions involved.  The results of this study may provide  data for future studies that will 
lead to interventions that influence the development, management, and long- term outcomes for 
pediatric and adult study participants  with USD . It is also possible that the information obtained because 
of this project will be used to develop clinical practice guidelines, which could directly benefit  patients  
with USD  in the future.  
 
3 OBJECTIVES AND  PURPOSE  
The primary aim of the study is to determine whether a multi -component program of behavioral 
interventions  to increase fluid intake  will result in reduced risk of stone disease progression over a 2 -
year period.  Under this aim, the study will test the following specific hypotheses, comparing 1) 
inter vention arm:  individuals participating in a multi -component program of behavioral interventions 
targeting increased fluid intake ( sufficient to achieve a urine output > 2.5 L daily  or > 30 mL/kg/day  for 
those study participants aged < 18 years  and weighing <75kg); versus  2) control arm : indivi duals 
receiving usual care : 
a. Primary hypothesis : Participants in the intervention arm will have a reduced risk of 
symptomatic stones  over 2 years . 
b. Secondary hypothesis #1 : Participants in the intervention a rm will have a reduced risk of 
stone disease progression (a composite outcome comprising symptomatic stone events, 
new asymptomatic stone on imaging, or stone growth of at least 2 mm  on imaging) over 2 
years.  
c. Secondary hypothesis #2 : Participants in the intervention arm will have a reduced risk of 
forming new asymptomatic renal stones over 2 years.  
d. Secondary hypothesis #3:  Fewer p articipants in the inter vention arm will exhibit  growth in 
existing renal stones of at least 2 mm on imagin g over 2 years.  
e. Secondary hypothesis # 4: Participants in the inter vention arm will be more likely to achieve  
goal  24-hour urine output.  
f. Secondary hypothesis # 5: Participants in the intervention arm will be  more likely to develop 
lower urinary tract symptoms  (LUTS) . 
g. Secondary hypothesis #6 : Greater urine output  will be associated with reduced risk of stone 
disease progression, controlling for medication use  (time updated) , disease severity and 
clinical characteristics (e.g., body mass index). 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  8 h. Secondar y hypothesis #7:  Participant s with pre -existing LUTS  will be  less likely to achieve 
24-hour urine output goals as compared to those  without pre -existing LUTS.  
4 STUDY DESIGN AND ENDPOINTS  
 
4.1 DESCRIPTION OF T HE STUDY DESIGN  
This is a two arm randomized c ontrolled trial that incorporates pragmatic features, an adaptable 
intervention, patient choice, and remote monitoring of fluid intake through a “smart” water bottle. The 
study period is 24 months  and will enroll approximately 1642 participants . Randomization will be 
stratified within a clinical center  by (adult vs. adolescent) and (first time vs. recurrent stone former). 
Intervention and control arm study participants  will receive a smart water bottle that records daily fluid 
consumption, usual care including guideline -based recommendations of adequate fluid intake to 
decrease kidney stone recurrence, and periodic 24 hour urine  collections.   
Participants in the intervention arm will receive an individualize d “fluid prescription”, which will be  the 
additional volume of fluid intake needed to maintain a urine output of at least  2.5 L/day  for study 
participants  aged at least 18  years (adults)  or 30 mL/kg/day for study participants aged 12- 17 years  
inclusive  (adolescents) and weighing < 75 kg; this additional fluid  will be consumed from the smart water 
bottle. The prescription will be determined by the following equation: Initial Fluid Prescription  = 1.2 x 
(2.5L – median urine volume on all 24- hour urine collections in the 12 months prior to enrollment). The 
fluid prescription may  be modified, as needed, based on the 24- hour urine volume measurement 
obtained approximately 2 weeks after  randomization. To reduce risk of unblinding treating provide rs, 
adjustments to the fluid prescription will be communicated by the study coordinator .  The intervention 
arm also includes a behavioral program that consists of financial incentives and structured problem 
solving (SPS) to maintain the recommended fluid intake. The intervention period can be divided into 
phases of “induction,” “consolidation,” “taper,” and “maintenance.” The induction phase comprises the 
first 6 months of the intervention , and will initia lly include eligibility for FI on 100% of days. Duri ng 
induction, the intensity of the intervention can be increased for those study participants  who do not 
consistently meet daily fluid intake goals by adding structured problem solving (SPS) to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake . 
The consolidation phase comprises the second 6 months  and enables some additional potential for SPS -
based adaptation of the intervention, but the frequency of the financial incentives will be slightly lower. The taper phase will comprise months 13 – 18, during whi ch SPS is withdrawn and financial incentives 
are fully tapered. In the final 6- month maintenance phase, participants will have access only to “low 
touch” and low cost interventions (e.g., text reminders ) that the participant selected to help sustain new 
habits of fluid consumption.    
Participants in the control arm will receive standard care instructions  according to  American Urological 
Association ( AUA ) guidelines  to increase overall fluid  consumption to achieve UOP of  at least  2.5 L daily. 
They will also receive a “smart” water bottle with capability to self -monitor their fluid intake, though the 
use of the “smart” water bottle is optional in the control arm .  Approximately 2 weeks after 
randomization, a 24- hour urine volume measurement will be obtained, to provide control arm 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  9 participants with initial feedback as to whether or not they are meeting the urine output goal ( urine 
output > 2.5 L daily  or 30 mL/kg /day  for those study participant s <75kg aged less than 18 years ).  
Participants in the control arm will not receive additional incentives, but will receive monetary 
compensation for completion of study activities (e.g., urine collections, study- related imaging, and study 
completion ).  
4.2 STUDY ENDPOINTS   
4.2.1 PRIMARY ENDPOINT  
Symptomatic kidney stone recurrence .  A symptomatic stone will be defined as any of the following:  
1. Stone passage  observed and/or captured by the study participant  
2. Procedural intervention for symptomatic stone  
3. Any procedural intervention for removal of asymptomatic renal or ureteral stone (See section 
10.4.2 for analytic details)  
4.2.2 SECONDARY ENDPOIN TS 
1. Asymptomatic formation of new stone detected by imaging 
2. Increased size of existing stone by ≥  2 mm in any dimension detected by imaging  
3. Composite outcome: symptomatic stone recurrence, asymptomatic stone formation, increase  of 
existing stone by ≥2 mm in any dimension detected by imaging 
4. 24 hour urine total volume  
5. Costs of study interventions and treatments for USD during the follow -up period  
6. Presence of lower urinary tract symptoms (Comprehensive Assessment of Self -reported Urinary 
Symptoms)  
 
4.2.3 EXPLORATORY ENDPOINTS  
1. Change in stone volume as estimated by imaging  
2. Change in body weight since study entry  
4.3 RANDOMIZATION  
Study participants will be randomized in a ratio of 1:1 to one of two parallel study groups, designated as 
“intervention” and “control”. Randomization will be stratified within a clinical center by (adult vs. adolescent) and (first time vs. recurrent stone former). Randomization will be conducted at the clinical 
center level in blocks of variable size to minimize potential confounders related to differences in site -
based care practices.   The randomization will be performed with the use of an i nternet -accessible 
integrated randomization module in the EDC system. 
The randomization scheme will be generated by a statistician at SDRC.  This statistician will not be a part 
of the analytic team for the study results, to minimize the possible introduction of bias into study 
results.   
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  10 4.4 REQUIREMENT FOR LO W URINE VOLUME  
Participants must have documented low urine volume to be eligible for the study. However, study 
investigators recognize that obtaining an accurate 24- hour urine volume poses challenges to efficient 
study recruitment given that participants will need to become oriented to the set -up and use of a smart 
water bottle.  
We will accept for eligibility a 24- hour urine volume within the 12 months prior to the study visit. If 
more than one 24-hou r urine specimen is available during that time period, then investigators will 
calculate the median volume of the available specimens; the median  AND the most recent volume must 
be less than 2.0 L or 2 5 mL/kg if age < 18 and  weight < 75 kg  (adolescents ≥75 kg will follow the 2.0L 
urine volume threshold) . Where possible, the investigators will also use conventional criteria (based on 
urine total creatinine) to assess if a urine specimen is an undercollection or overcollection. If no urine specimen during the 12 months  prior  to the day of screening is available, investigators will ask 
otherwise eligible participants to complete a 24- hour urine collection for volume , osmolality,  and 
creatinine excretion.  
5 STUDY ENROLLMENT A ND WITHDRAWAL 
 
5.1 PARTICIPANT  INCLUSION CRITERIA  
1. Aged  ≥ 12 years  
2. At leas t 1 symptomatic stone event (passage or procedural intervention) within 3 years prior 
to enrollment  or a symptomatic stone event within 5 years if the patient also has new stone 
formation detected on imaging during the last 5 years . Symptomatic stone defined as any of 
the following:  
a. Stone passage  
b. Procedural intervention  
c. Radiographically or ultrasonographically confirmed stone with any of the following:  
i. Gross hematuria  
ii. Renal colic or atypical abdomin al pain attributed to the stone , as det ermined by 
a treating provider  
iii. A clinical pattern of intermittent symptoms consistent with intermittent 
obstruction  at the ureteropelvic junction, as determined by a treating provide r 
3. Low 24 -hr urine volume  
a. ≥18 years old: < 2.0 L/day  
b. <18 years old and weight <75kg: <2 5 ml/Kg/day  (adolescents ≥75 kg will follow the 2.0L 
criteria)  
4. Able to provide informed consent (parent al permission  for children)  
5. Own ing and willing to use a smartphone  or other device (e.g., tablet)  compatible with the 
study- provided wireless enabled  “smart”  water bottle  
5.2 PARTICIPANT  EXCLUSION CRITERIA  
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  11 1. Spinal cord injury 
2. Currently undergoing active treatment for cancer except basal cell skin cancer , or patients 
with a history of cancer who completed their initial therapy <  1 year before screening . 
3. Known infectious (struvite), monogenic or other causes of stone disease for which therapies 
are likely to significantly alter course of stone disease  
a. Cystinuria  
b. Primary hyperoxaluria  
c. Primary xanthinuria  
d. Primary hyperparathyroidism  
e. Sarcoidosis  
f. Medullary sponge kidney 
4. History or presence of hyponatremia (serum sodium <130 mmol/L) or hypo -osmolality 
(serum osmolality <275 mosm/kg)  
5. Study participants  with comorbiditi es that preclude high fluid intake or prior surgery 
precluding high fluid intake or leading to GI fluid losses  
a. History of or current Crohn’s disease, ulcerative colitis, short gut syndrome (e.g. 
ileostomy , bowel bypass surgery to treat obesity, small bowel  resection ), chronic 
diarrhea, or GI tract ostomy.  
b. History of malabsorptive (e.g., Roux -en-Y gastric bypass) or restrictive (e.g., sleeve 
gastrectomy) bariatric surgery procedures  
c. Congestive heart failure  
i. NYHA class II or greater, and/or  
ii. Hospital admission in the past year for heart failure  
d. Lung disease with a home oxygen requirement  
e. Chronic kidney disease (eGFR <30 ml/min/1.7 m2 over a 3 -month period)  
i. For adults  (age ≥18), we will use the CKD -Epi equation which requires the 
measurement of serum  creatinine only.  
ii. For children  (age <18), we will use the bedside Schwartz (CKiD) formula.  
f. Nephrotic syndrome (>3.5 grams of protein per 24 hours)  
g. Cirrhosis with ascites  
6. Women  who are currently pregnant  or planning pregnancy within 2 years  
7. Renal transplant r ecipient  
8. Bedridden study participants  (ECOG ≥ 3)  
9. Uncorrect ed anatomical obstruction of the urinary tract  
10. History of r ecurrent urinary tract infections  (> 3 UTI/year proven by urine culture)  
11. Exclusions due to medication use:  
a. Chronic use of lithium  
b. Long -term  glucocorticoid use (> 7.5 mg prednisone daily for > 30 days prior to enrollment)  
c. Intake of narcotic medication on a daily basis for >30 days prior to enrollment  
d. Supplemental Vitamin C ( > 1 g daily ) 
12. Individuals with stones that have developed after the ini tiation of medications that are 
strongly associated with USD  such as carbonic anhydrase inhibitors (acetazolamide, 
topiramate, zonisamide), high dose vitamin C  ( > 1 g daily), high dose calcium supplementation 
(> 1,200 mg daily) AND who have discontinued o r plan to discontinue these medications. 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  12 13. Individuals with stones composed of medications that may crystallize in the urine 
(guaifenesin, sulfonamides,  triamterene, and the protease inhibitors indinavir and nelfinavir) 
AND who have discontinued or plan to discontinue these medications.  
Note: Individuals who are on long- term medications that increase the risk of stone disease, 
who cannot stop these medications due to other chronic conditions  (e.g., HIV) and who may 
reduce their risk for stone recurrence through increased fluid intake , will be eligible to 
participate in the trial.  Examples of these medications include:  
a. Carbonic anhydrase inhibitors (acetazolamide, topiramate, zonisamide)  
b. Medications that may crystallize in the urine (guaifenesin, sulfonam ides, triamterene, and  
the protease inhibitors indinavir and nelfinavir). 
14. Study participants  <2 yrs life expectancy  
15. Non- English Speakers  
16. History of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)  
17. Anatomical urologic abnormalities includin g ileal conduits, horseshoe kidney, megaureter or 
solitary kidney 
18. Psychiatric conditions impairing compliance with the study  
19. Vulnerable population (prisoner and/or cognitive impairment that the investigator feels will 
impact the study participant ’s ability  to participate in the protocol ) 
20. Individual who will be unable to participate in the protocol in the judgment of the investigator  
 
5.3 STRATEGIES FOR RECRU ITMENT AND RETENTION  
Adolescent and adult study participant s will primarily be recruited into the study via two routes: a) 
referrals from their primary urologist or nephrologist in the USDRN Clinical Centers  (CC) ; and b) 
surveillance of appropriate study participants  in the EMR. However recruitment via other routes  such as 
advert isements and press releases is allowed . Eligible study participants  may  be contacted by phone, 
letter, email  or secure EMR messaging prior to in -person recruitment . Their  providers will be alerted 
about plans for recruitment, as appropriate . EMR filters may be implemented  to alert study staff about 
potentially  eligible study participants’ upcoming routine clinic visits. At the initial contact with the 
participant, s tudy staff will explain  the study rationale and goals, as well as the requirements for 
participation. Interested participants may  be provided with copies of the  informed consent  documents 
and eligibil ity questionnaires  to review and complete.   Informed consent and enrollment wil l be 
obtained by CC -based staff.   Participation will be completely voluntary and will not  affect the  
participant’s  clinical care. If adult study participants and adolescent study participants (with consent also 
provided by parents/caregivers of adolescent study participant s) are interested in participating, USDRN 
CC PIs or their designated staff will consent the study participant  and parents/caregivers for enrollment.  
All participants will receive modest compensation for the time spent  on completion of study -related 
procedures.    
 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  13 5.4 PARTICIPANT  WITHDRAWAL  OR TERMINATION  
 
5.4.1 REASONS FOR WITHDRAW AL OR TERMINATION  
Study participant s may withdraw from study intervention or the entire study at any time during the 
study without prejudice.  If a participant withdraws from study intervention, other study assessments 
will continue through the end of the study.  The participant may be discontinued from study 
intervention  at the discretion of the investigator if medically necessary or if any untoward effects occur. 
In addition, a study participant  may be withdrawn by the investigator or the sponsor if the study 
participant  violates the study plan or for administrative and/or other safety reason.   Study coordinators 
will report reasons for stud y withdrawal in the EDC database .  
 
5.4.2 HANDLING OF PARTICIPANT  WITHDRAWALS OR T ERMINATION  
The investigator or designee will notify SDRC  immediately when a study participant  has been 
discontinued or withdrawn from study intervention  because of an adverse experience. When a study 
participant  discontinues or is withdrawn from the study before study completion, the participant will be 
asked to complete activities scheduled for the Month 24  study visit at the time of discontinuation. Any 
adverse experiences that are present at the time of discontinuation/withdrawal should be reported and followed up in accordance with the safety requirements outlined in Section 8 Assessment of Safety .  
 
6 STUDY INTERVENTION 
 
6.1 STUDY I NTERVENTIONS  AND CON TROL DESCRIPTION  
 
6.1.1  OVERVIEW   
Control  Intervention  
Platform  Participants will be 
provided with a w ireless -
enabled “smart”  water 
bottle .  
Participants  will be allowed, 
but not  required , to use or 
sync the water bottle  with 
their mobile device  Wireless -enabled “smart”  water bottle  
Participants must sync water bottle  with their mobile 
device daily  
Fluid Goal  Usual care (sufficient fluid 
intake to achieve UOP  ≥ 
2.5L per 24 hours  or 
30/ml/kg/day for 
participants <18 years and 
<75kg ) 120% of baseline UOP deficit via the water bottle , with 
modification possible at Week 2 ; 24-hour urine volume 
check @ 2 weeks , 6 months, 12 months, and 18 
months.  
  
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  14  
Control  Intervention  
24-hour urine volume check 
@ 2 weeks , 6 months, 12 
months, and 18 months.  
Behavioral Intervention 
Program  none  Months 0 -6 (Induction):  
• Daily f inancial incentive for success at meeting 
fluid intake goal via water bottle (FI possible 
100% of days)  
• Structured Problem Solving (SPS)  
o Non-adherence trigger  if fluid goal 
was achieved less than 80% of days over two weeks (i.e. , >3 days where 
fluid goal was not met during 14 day period)  for two  14-day assessment 
periods . 
• SPS “Booster” (intensified counseling)  
o Non-adherence trigger  if fluid goal 
was achieved less than 80% of days  
over two weeks  (i.e., >3 days where 
fluid goal was not met during 14 day period)  for two 14 -day assessment 
periods  following initial SPS.  
 
Months 7 - 12 (Consolidation) : 
• Daily f inancial incentive for success at meeting 
fluid intake goal via water bottle possibility of receiving incentive  for 80% of da ys [24] in 1 
month period) 
• Structured Problem Solving (SPS)  
o Non-adherence trigger  if fluid goal 
was achieved less than 80% of days  
over two weeks  (i.e., >3 days where 
fluid goal was not met during 14 day period)  for two 14 -day assessment 
periods . 
• SPS “Boos ter” (intensified counseling)  
o Non-adherence trigger  if fluid goal 
was achieved less than 80% of days over two weeks (i.e., >3 days where fluid goal was not met during 14 day period) for two 14 -day assessment 
periods following initial SPS.  
Months 13 – 18 (Tapering) : 
• Taper daily f inancial incentive (75 % of days at 
month 13 and 15% of days at month 18)  
• Self-selected/low touch intervention(s)  
o Text/phone reminders  
o Commitment contract  
o Social intervention (e .g., team)  
Months 19- 24 (Maintenance) : 
• Self-selected/low touch intervention(s)  
o Text/phone reminders  
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  15  
Control  Intervention  
o Commitment contract  
o Social intervention (e .g., team)  
o Feedback of adherence  
Stone -directed 
pharmacological or 
urological care  Per primary stone treating 
provider  Per primary stone treating provider  
   
 
6.1.2  FINANCIAL INCENTIVES  
As described above , a substantial percentage of USD patients  have persistently low fluid intake, despite 
evidence that low fluid intake promotes stone recurrence. Maintaining fluid intake sufficient to prevent 
USD is difficult because the short -term benefits of fluid intake are not apparent since symptomatic stone 
episodes commonly take place after months or years without symptoms. Financial incentives may help bridge the gap between the perceived benefits of daily fluid intake and the future benefit of preventing USD  recurrence by offsetting present -bias (tendency to focus on the present and heavily discount the 
future) through regular, ongoing positive reinforcement.
36,37 The immediate reinforcement provided by 
financial incentives can focus attention on adherence to fluid intake recommendations. The rep eated, 
small payoffs increase the attractiveness of the incentive by giving participants intermittent positive reinforcement and take advantage of prese nt-bias in decision -making surrounding adherence. 
Additionally, we will incorporate messages that inform  non- adherent study participants  about their 
missed opportunity for a payout; future adherence is thus further encouraged by harnessing regret -
aversion (the tendency to make decisions based on desire to avoid losses and regret).
36,38- 40 
We will use financial incentives during the first 18 months of the study. Eligibility for these incentives will be calculated daily (although, as noted elsewhere, incentives will not be delivered to participants daily during later phases of the trial). These incentives will be structured as a “loss” incentive, which has been 
shown to produce the greatest sustained improvement in health behaviors  compared to other incentive 
delivery structures .
41 Each participant will be credited $1.50 for each day for which financial incentives 
are available. The participant will keep the $1.50 if they met or exceeded the prescribed fluid volume for 
that day and will forfeit the $1.50 if he/she did does not meet the goal. The intervention period will be 
divided into 6 month phases of “induction”, “consolidation”, “taper”, and “maintenance.” The utilization and frequency of financial incentives will vary across these periods. 
At the start of each month in the trial, each participant will be credited with funds in their Way to Health account corresponding to the total possible rewards available during that month (described below) in the event of meeting fluid intake goals each day. The funds credited to the participant’s account that 
month (and total earnings since starting the trial) can be tracked by each participant easily through his 
or her Way to Health account.   Participants will receive a distribution of funds from their account 
approximately every 4 weeks.  
  
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  16 Induction  (months 1- 6): Financial incentives available for 100% of days  
  
Consolidation (months 7- 12): Financial incentive available for 80% of days during the study 
period , i.e. twenty -four days during a 30 day  month during this phase will be randomly assigned 
to have a financial incentive available.  
  
Taper  (months 13- 18): Decrease in the frequency of financial incentives  
  Month 13: 75% of days (22)  
  Month 14: 65% of days (19)  
  Month 15: 50% of days (15)  
  Month 16: 35% of days (10)  
  Month 17: 25% of days (7)  
  Month 18: 15% of days (4)  
  
Maintenance (months 19- 24): no financial incentives  
 
In order to be eligible for the financial incentive, the participant must:  
1) Drink a minimum of the prescribed fluid volume from the smart water bottle  
2) Sync the wate r bottle to their mobile device as instructed  
 
The participants will receive the following feedback through their choice of text message , email, or a 
combination thereof.   
Feedback messages will leverage the principle of loss aversion by reminding study participants  that 
money in their account was retained or lost depending on their fluid intake. Participants should be 
motivated to prevent further losses on subsequent days.  Details on the messaging that participants may 
receive are included in the Way to Health MOP.  
 
6.1.3  STRUCTURED PROBLEM SOLVING  
Structured Problem Solving (SPS)  is well suited to the substantial challenges of sustaining adequate fluid 
intake, which requires tailoring the advice and encouragement to each patient’s needs. For example, 
each PUSH trial participant  will have different schedules (some individuals may spend most of the day 
outside the house, requiring them to carry a bottle with them), health literacy, health conditions (such 
as urinary incontinence), and social support that must be addressed to change their fluid intake. Behavior change also requires repeated feedback, which SPS is inherently structured to provide. The SPS approach can meet the challenge of helping PUSH study participants  identify feasible solutions to 
overcome these diverse barriers to increase fluid intake.  
Participants assigned to the  intervention arm who do not meet  the daily fluid goal for ≥80% of days (11) 
over two 14 -day periods during months 1- 12 will receive SPS to identify their individual, specific  barriers 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  17 to fluid intake and develop a systematic approach to learn how to overc ome these barriers.  
A health coach with specific expertise  or specifically trained by an expert  for this role will administer SPS.   
Participants  randomized to the intervention arm who meet criteria for receiving SPS  will meet with the 
health coach initially for approximately 30 minutes.  This meeting could take place in person, over the 
phone, or virtually through audiovisual media . The introductory session will consist of education 
concerning the prescribed fluid intake regimen, adherence expectations, and any fluid intake 
misperceptions, as outlined in the  SPS Manual of Procedures . There will be scheduled follow- up feedback  
sessions to review the prior participant’s  daily fluid intake and allow for problem solving of new issues. 
Participants will also receive daily, automated feedback of their fluid intake via Way to Health (based on 
smart  bottle data).  
The coach will record root causes of fluid intake below goal and identify successful approaches used to 
address the major barrier(s). During months 1- 12, participants who have received SPS, but still have fluid 
adherence < 80% of days over two 14- day assessment periods (i.e. , >3 days where fluid goal was not met 
during 14-day period), will receive up to 2 “booster” sessions, which will consist of intenstified counseling 
and root cause analysis and remediation of reasons for lack of adherence.  Booster SPS sessions may be delivered in person or remotely (audio/video or a udio -only interface) , in accordance with the SPS MOP .    
If, after 2 booster sessions, adherence is still below 80% for subsequent assessment periods, the 
participant will be offe red the opportunity to select  one or more “low touch ” interventions (e.g. 
automated fluid intake  reminders from HidrateSpark) to continue throughout the remainder of the study 
period. The rationale is that application of an intensive intervention that has not resulted in behavior 
change will be unlikely to do so with continued application and may decrease participant retention. Regardless of whether the participant in the intervention arm has received SPS, he/she will continue to 
be eligible for financial incentives according the the schedule described in Section 6.1.2.  
The health coach will undergo structured training to gain expertise in the specific nutritional needs of 
study participants  and strategies to improve adherence. Health coaches will use the Way to Health 
platform to review fluid intake and urine  volume and have meetings to share advice about how to achieve 
the fluid intake goals.  
Additionally, SPS -based communications between the health coach  and participants will be logged in the 
EDC database . 
6.2 STRUCTURED PROBLEM S OLVING FIDELITY  PROCEDURES  
The initial SPS sessions ( in person or remote using audio- visual media) will be digitally recorded  (audio 
only)  and a random sample from each USDRN -CC will be reviewed to assess the fidelity of the facilitator 
to the intervention , as outlined in the Manual  of Procedures .  
 
   
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  18  
7 STUDY PROCEDURES AND  SCHEDULE  
 
7.1 STUDY PROCEDURES/EVA LUATIONS  
7.1.1  STUDY -SPECIFIC PROCEDURES   
Study participants will undergo laboratory and imaging evaluations at specified intervals during the 
study period (see Schedule of Events, 7.3).   
Screening  
At screening, participants will complete serum chemistry, serum osmol ality , 24- hour urine creatinine,  
24-hour urine total volume,  24-hour urine osmolality , and review of medical history, medications, and 
demographic information.  
In place of new testing at screening, w e will accept for eligibility : 
• Blood laboratory results within 18 months prior to the screening visit, provided that the 
participant does not meet any  of these risk criteria for hyponatremia:  
o Age 65 or older  
o Taking thiazide diuretics  
o Taking SSRI medications  
o Last eGFR 30 – 45 mL/min/1.73 m2 
If a participant has completed a blood metabolic panel in the 30 days prior to screening, those 
results can be used to assess blood sodium levels and the participant’s risk for hyponatremia.  
 
• A 24-hour urine collection within the 12 months prior to the screening visit. If more than one 24-
hour urine specimen is available during that time period, then investigators will calculate the 
median volume of the available specimens; the  median value AND the  most recent volume must 
be less than 2.0 L or 2 5 mL/kg if  age < 18 and  weight < 75 kg  (adolescents  ≥75 kg will follow the 
2.0L criteria) . 
If a participant completed one or more 24 hour urine tests in the 12 months prior to screening and the 24- hour urine panel was run, the results of the most recent panel will be accepted in 
place of a new collection provided that the following were obtained:  
• Total Volume  
• Creatinine  
• Citrate  
• pH 
• Sodium 
• Uric acid  
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  19 • Oxalate  
• Calcium  
If the results listed were not obtained, study participants will undergo a new screening 24- hour  
collection and the full  urine panel.  
Baseline   
At the baseline visit study participants will have their weight and height recorded and undergo baseline 
imaging (low dose CT for participants aged ≥  18 years, renal ultrasound for those aged < 18 years  at 
enrollment ; imaging details in Manual of Procedure s). Adult females (ages 18 years and older) of 
childbearing potential will undergo a pregnancy test (urine HCG) prior to their baseline imaging.    
In place of new imaging at baseline, we will accept:  
• Stone protocol CT scans (for adult participants) perfo rmed in the 3 months prior to the baseline 
visit, or 
• Renal ultrasound (if age <18) performed in the 3 months prior to the baseline visit   
Provided that  
o They are reviewed by the Investigator and deemed comparable to the imaging that 
would have been completed at baseline , with views in 3 dimensions.   
o The participant has not had a stone passage event or removal procedure since the 
completion of the scan.  
In order to facilitate recruitment, the Bas eline  imaging, and the associated pregnancy test for adult 
females, may be waived for participants : 
o  Enrolled and randomiz ed from locations other than the 6 primary Clinical Centers/study 
sites  
o Enrolled from an existing Clinical Center/site, but who are otherwise eligible but are 
refusing participation in the study because of imaging  
The waiver of imaging will be documented in the study database. Adult female participants will be ask ed 
to verbally confirm that they are not pregnant or planning to become pregnant during their time in 
study.  
All participants will be randomized to either the intervention arm or the control arm. Participants in the 
intervention arm will receive a smart water bottle, and will create accounts with Hidrate Spark, Way to 
Health,  and in the EDC database, and will receive their initial fluid prescription. Participants in the 
control arm will receive the smart water bottle but will not be required to create a Hidrate Spark 
account ; they will however be required to create Way to Heal th and EDC database accounts.  
Note : The screening and baseline visits may be combined into a single, in- person visit, provided that:  
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  20 1. Informed consent is obtained from the participant prior to any study procedures or collection of 
data in the EDC database.  
2. Participant eligibility must be confirmed by the Investigator prior to randomization.  
2 Weeks  After Randomization  
At 2 weeks (± 7  days) post -randomization , participants in intervention and control arms will complete a 
24 hour urine collection, include volume and panel .  In the intervention arm, this 24 hour urine total 
volume may  be used to adjust the initial fluid prescription. In the  control arm, study participants will be 
notified that their 24- hour urine total volume is at or above the target volume (2500 mL/24 hours  or 30 
mL/kg for those study participants  <75kg aged less than 18 years  ) or below the target volume, and 
advised about their fluid intake in accordance with guideline -based recommendations of adequate fluid 
intake . 
 
Follow-U p Procedures  
All study participants will receive emails from the EDC database prompting them to log in to their 
account (which they created at baseline) and complete the follow -up visit questionnaire  at months 3, 6, 
9, 12, 15, 18, 21, and 24. As a part of the questionnaire, they will  be asked to provide their current 
weight  and height, and answer questions pertaining to the ir stone disease . Adult participants will be 
prompted to also complete the lower urinary tract symptoms questionnaire (the CASUS) at 6, 12, 18 and 24 months.  
All study participants will undergo follow -up imaging at 24 months (low dose CT for participants aged ≥ 
18 years  at enrollment, renal ultrasound for those aged < 18 years  at enrollment; imaging procedure 
details in Manual of Procedures ).  Adult females (ages 18 years and older) of childbearing potential will 
undergo a pregnancy test (urine HCG) at mont h 24 prior to the CT scan.     
In place of new imaging at Month 24, we will accept:  
• Stone protocol CT scans (for adult participants) performed in the ±6 0 day window for  the Month 
24 visit, or 
• Renal ultrasound (if age <18) performed in the ±60 day window for the Month 24 visit   
Provided that  
o They are reviewed by the Investigator and deemed comparable to the imaging that 
would have been completed at Month 24 , with views in 3 dimensions.   
o The participant has not had a stone passage event or removal procedure since the 
completion of the scan.  
In order to facilitate recruitment, the Month 24  imaging, and the associated pregnancy test for adult 
females,  may be waived for participants : 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  21 o  Enrolled  and randomized from locations other than the 6 primary Clinical Centers/study 
sites  
o Enrolled from an existing Clinical Center/site, but who are otherwise eligible but are 
refusing participation in the study because of imaging  
The waiver of imaging will be documented in the study database.  
In addition, at 6, 12, 18 and 24 months, participants will undergo 24- hour urine total volume, 24- hour 
urine creatinine, and 24- hour urine osmolality assessment.  If a participant completed a 24 hour urine 
test with in the ±30 day window for the Month 6, 12, 18 and with in the ±60 day window for the Month 
24 visit, the results of the most recent panel will be accepted in place of a new collection provided that 
the following were obtained:  
At Months 6, 12, 18:  
• Total Volume  
• Creatinine  
At Month 24:  
• Total Volume  
• Creatinine  
• Citrate  
• pH 
• Sodium 
• Uric acid  
• Oxalate  
• Calcium  
• Phosphate  
 
A 24-hour urine panel will also be performed at Month 24, although results of thi s test will not be 
available to the DSMB until study conclusion.  
Adolesecents  who turn 18 years old during the study will continue to perform the adolescent 
procedures (no LUTS questionnaire, ultrasound scans in place of CT) so that their data is comparable 
throughout their participation.  
7.1. 3 STANDARD OF C ARE STUDY PROCEDURES   
Current guidelines recommend annual imaging to detect asymptomatic stone activity (formation or growth) for individuals with urinary stone disease.  Study participants may  undergo low dose CT scan 
(renal ultrasound for study participants age < 18 years at enrollment) at 12 months as part of standard 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  22 of care monitoring for their urinary stone disease, or as a part of a surgical procedure to remove a stone .  
Results of these studies may be available through the treating physician. Data from other stone -directed 
imaging studies performed at the direction of the participant’s treating physician at 12 (+/- 1) months 
and throughout the study follow -up period may also be collected.   
7.1. 4 BIOREPOSITORY SPECIM EN C OLLECTION   
 
In addition to study -specific laboratory tests, blood, urine and stone samples as well as stool samples  
will be obtained for use in future studies.  These samples along with the study data (including digital 
imaging data) will be stored in the NIDDK Repositories, supported by the National Institutes of 
Health.   These data and stored samples will be available to use in research for the study of USD after 
PUSH is  complete.    
 
Biospecimens collected as part of the study will include:  
 
• Whole blood (DNA)  
• Serum  
• Plasma 
• Urine  
• Stool   
• Kidney stone sample (if available)  
 
7.1. 5 DATA COLLECTION  PROCESS  
Study data from the se sources will be integrated at the SDRC.   
 
Clinical Centers /Sites : Clinical C enter /site  personnel will complete eCRFs (in the EDC database managed 
by the SDRC) during the study period covering participant eligibility and baseline information,  outcome 
events, study procedures (other than 24 hour urine collection), and safety monitoring (see Section 8).  
 
Way to Health :  The study will leverage the NIH -funded Way to Health web- based platform  at the 
University of Pennsylvania (UPENN) (RC2- AG036592- 01). This platform for clinical trials implementation 
provides a secure, efficient, user -friendly approach to monitoring partici pation,  delivering 
feedback /communications  (e.g., through emails, texts or phone messages using Automated Interactive 
Voice Response) and incentives in an automated fashion. All USDRN CCs will leverage the existing Way 
to Health infrastructure through admi nistration of financial incentives and collection of fluid 
consumption data in real -time . These data will be securely  transmitted to SDRC periodically as specified 
in the PUSH Manual of Procedures and the SDRC/WTH Data Transfer Agreement . 
 
Hidrate Spark :  Data regarding participants’ daily fluid intake will be securely transmitted to Way to 
Health on a daily basis. All participants in the intervention arm will have their d ata transferred. O nly 
participants in the control arm who choose to set- up their smart  water bottle will have data transmitted.  
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  23  
Core Lab : 24- hour urine collections will be processed at a core lab facility for the USDRN , located at 
University of Texas Southwestern .  Results will be securely transmitted to SDRC periodically as specified 
in the PUSH Manual of Procedures and the SDRC/UTSW Data Transfer Agreement . 
 
All data and records generated during this study will be kept confidential in accordance with Institutional policies and Health Insurance Portability and Accountability  Act (HIPAA) o n study 
participant  privacy. Investigators and other site personnel will not use such data and records for any 
purpose other than conducting authorized research . IRB approvals will be obtained prior to initiating 
study activities.    
 
7.2 LABORATORY PROCEDURES/EVALUATIO NS 
 
7.2.1  CLINICAL LABORATORY EVALUATIONS  
Study participants will complete periodic clinical laboratory evaluations, as outlined in the Schedule of 
Events Table (7.3).   
These will include 24- hour urine volume, 24- hour urine analysis ( calcium, creatinine, citrate, 
phosphorous, pH, sodium, urea nitrogen, oxalate, chloride, ammonium, magnesium, potassium, uric 
acid, sulfate, qualitative cystine[baseline]) and 24- hour urine osmolality.  Supersaturations of calcium 
oxalate, calcium phosphate and uric acid will also be included. Urine Hcg will be performed on adult 
females of childbearing potential  in association with CT scans, only; when a waiver of imgaging is 
granted, this testing is also waived . Serum chemistry and osmolality will be obtained on participants 
without recent test results.  
7.2.2  OTHER  ASSAYS OR PROCEDURES  
Study participants will undergo baseline and end-of-study imaging (low dose CT for participants aged ≥ 
18 years, renal ultrasound for those aged < 18 years  at enrollment; imaging procedure details in Manual 
of Procedures ) during the study, as outlined in the Schedule of Events Table (7.3) . Historical records will 
be accepted in place of the baseline CT scan, as explained in Section 7.1.1.  Waivers of imaging will be 
allow ed, a s explained in Section 7.1.1. 
7.2.3  SPECIMEN PREPARATION , HANDLING, AND STOR AGE  
Specimen preparation, handling and storage will be in accordance with the PUSH Manual of Procedures and the clinical centers’ institutional procedures . 
 
7.2.4  SPECIMEN SHIPMENT  
Specimen shipment for study specimens and specimens collected for the NIDDK R epository shall be 
shipped according to the procedures outlined in the PUSH Manual of Procedures .
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  24 7.3 S CHEDULE OF E VENTS TABLE   
 
Procedure  Screen  Baseline  2 weeks ± 
7 days  3 mos ± 
30 days  6 mos ± 
30 days  9 mos ± 
30 days  12 mos ± 
30 days  15 mos ± 
30 days  18 mos ± 
30 days  21 mos ± 
30 days  24 mos ± 
60 days  
Informed Consent  X           
Email/Telephone 
Follow Up     X X X X X X X X 
Serum 
chemistry/eGFR  X           
Serum osm olality  X           
Hcg (urine dip) α  X         X 
Randomization   X          
Provide smart water 
bottle *  X          
24-hour urine panel† X†  X†        X 
24-hour urine TV  X‡  X  X○  X○  X○  X○○ 
24-hour urine Cr  X‡  X  X○  X○  X○  X○○ 
24-hour urine osm  X‡  X  X○  X○  X○  X○○ 
Imaging α  X     X§    X~ 
Medical History  X          X 
Weight  and Height   X  X X X X X X X X 
LUTS assessment  ‖  X   X  X  X  X 
* All participants are provided with a smart water bottle, but only participants randomized to the intervention arm are require d to set -up the bottle and use it 
during the study.  
†24-hour urine panel includes: calcium, creatinine, citrate, phosphorous, pH, sodium, urea nitrogen, oxalate, chloride, ammonium, magnesium, potassium, uric 
acid, sulfate, qualitative cystine.  Qualitative cystine will only be performed for Week 2 collection.  A Screening/Baseline 24 hour urine panel  will only be done if 
the participant does not have the  historical panel results needed for determining eligibility (see Section 7.1.1).  
‡A single 24 -hour urine sample will be collected at screening  for participants without any 24 -hour urine tests in the 12 months prior to the Screening visit  and 
the central lab will run urine volume, creatinine and osmolality only on this sample. For participant with prior 24 -hour urine tests but without the results listed 
in Section 7.1.1, a new sample will be collected at screening and the full panel w ill be run on this sample .  
○  For Months 6, 12, 18, a clinical 24 hr urine can be used in place of a new collection provided it is within the ±30 day window of that visit and it includes 
volume and creatinine.  
○ ○  For Month 24, a clinical 24 hr urine can be used in place of a new collection provided it is within the ± 60 day window of that visit and it includes the results 
listed in Section 7.1.1.  
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  25 α Imaging at Baseline and Month 24 , and the associated pregnancy testing for adult females, may be  waived for participants enrolled from  locations other than 
the primary Clinical Centers/sites , or who are enrolled from an existing CC  and qualify but are declining participation in the study because of imaging . Adult 
female participants will be asked to verbally confirm that they are not pregnant or planning to become pregnant during their time in study.  
§ Imaging = low dose CT (adults); renal u/s (adolescents) ; imaging at 12 months considered standard of care procedure  and not required . SOC imaging done at 
any point during the participant’s follow -up will be collected and entered in the EDC database.  
~ For Month 24, imaging performed for clinical care can be used in place of new imaging provided it was completed within  ± 60 days  of the visit, and the 
criteria in Section 7.1.1 are met.  
‖ Assessment of Lower Urinary Tract Symptoms in study participants aged ≥18 years using Comprehensive Assessment of Self -Reported Urinary Symptoms  
(CASUS)
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  26  
7.4 CONCOMITANT MEDICATIONS,  TREATMENTS, AND PRO CEDURES  
Participants in bo th arm s will continue to receive clinical care from their treating urologist and/or 
nephrologist. Study participants will not be permitted to enroll in other trials of novel therapeutics to 
prevent or treat urinary stone disease.  
Medications that reduce kidney stone recurrence are permitted in both arms. These medications 
include:  
1) sodium or potassium citrate  
2) thiazide diuretic  
3) allopurinol  
Any surgical procedure for treatment of a kidney stone is permitted. These  procedures include:  
1) ureteroscopy  
2) shock wave lithotripsy  
3) percutaneous nephrolithotomy  
An outcome adjudication committee  will adjudicate all procedures performed to determine if they were 
performed for a symptomatic stone, which is the primary outcome measure.   
7.4.1. CHANGES IN PARTICIPA NT CLINICAL STATUS OR TREATMENT DURING THE TRIAL  
Analyses will adhere to an intention to treat principle, such that every attempt will be made to collect outcome information on all participants (even if the participant is unwilling or unable to adher e to the 
assigned intervention).  It is possible that some participants may start new clinical regimens or develop 
new clinical conditions during the  trial that were contraindications to enrollment. The following characteristics  or treatments would require cessation of the intervention:  
Incarceration , hyponatremia requiring medical intervention, and/or any condition preventing high fluid 
intake such as advanced CHF or cirrhosis with ascites.  
The following characteristics or treat ments would not require cessation of the intervention, but should 
be recorded by the study staff:  
Study participants who develop struvite stones, cystine stones, or who started lithium use, diuretic use, topiramate use, ket ogenic diet , chronic corticostero id use, supplemental vitamin C;  or develop  
recurrent UTIs .   
Study participants who become pregnant during the study will be removed from the study  with their 
pregnancy followed until final outcome (as described in 8.4.5).   
 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  27 7.5 PROHIBITED MEDICATIO NS, TREATMENTS, AND PROC EDURES  
The following medications, treatments, and procedures are prohibited at screening, and should result in 
a potential participant being deemed a screen failure:   
1) Lithium use  
2) Loop diuretic use  
3) Interventions and medications that cause stones  
a. Chronic corticosteroid use (>1 month)  
b. Supplemental Vitamin C  (>1 g daily)  
4) Novel therapeutics for stone prevention  
  
8 ASSESSMENT OF SAFETY  
 
8.1 SPECIFICATION OF  SAFETY PARAMETERS  
Participation in the proposed study is completely voluntary. The research team will institute strict 
procedures to maintain confidentiality. All data and records generated during this study will be kept confidential and in accordance with institutional policies and HIPAA priva cy policies . Study participant s 
will be assigned a unique identification code that will be used as the sole identifier. Study  participant s 
and families will have direct access to the study team as a means to voice any questions, concerns, or 
reservations. Contact information will be provided at the time of consent. Should any specific concerns 
arise, the study team will intervene to address  problems including, if needed, a change or 
discontinuation of study procedures. The appropriate institutional IRBs and DSMB  will be informed of 
serious adverse events or protocol deviations, as outlined below . 
8.1.1  DEFINITION OF ADVERS E EVENTS  (AE)  
Adver se Event  
An adverse event (AE)  is any untoward medical occurrence associated with the use of a  study 
intervention  in a study participant .  An AE can, therefore, be any unfavorable and unintended sign 
(including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product or biologic. Diseases, signs, symptoms, or laboratory abnormalities already existing at the time of consent are not considered AEs unless they worsen (i .e., 
increase in intensity or frequency). Surgical procedures themselves are not AEs; they are therapeutic measures for conditions that require surgery. The condition for which the surgery is required may be an AE. Surgical procedures planned before randomization and the conditions leading to these measures are not AEs.  
8.1.2  DEFINITION OF S ERIOUS ADVERSE EVENT S (SAE)  
Serious Adverse Event  
An AE or SAE is consi dered serious if the investigator believes any of the following outcomes may occur:  
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  28 1. Death.  
2. Life-threatening AE: places the study participant, in the view of the investigator, at immediate 
risk of death at the time of the event as it occurred. It does not include an AE that, had it 
occurred in a more severe form, might have caused death.  
3. Persistent or significant disability or incapacity or substantial disruption of the ability to conduct normal life functions.  
4. Congenital abnormality or birth defect.  
5. Require s inpatient hospitalization or prolongation of existing hospitalization with the 
following exceptions:  
• Preplanned (before the study) hospital admissions, unless the hospitalization is prolonged 
• Planned admissions (as part  of a study)  
• Rehospitalizations  (after discharge from index hospitalization) of less than 24 hours  
• Elective procedures  
• Emergency department visits  
Important medical events that may not result in death, be life threatening, or require inpatient 
hospitalization may be considered a serious adverse event (SAE) when, based on appropriate medical judgment, they may jeopardize the study participant  and/or r equire medical or surgical intervention to 
prevent one of the serious outcomes listed above. This determination is based on the opinion of the 
Investigator.  
8.1.3  DEFINITION OF UNANTI CIPATED PROBLEMS  (UP)  
Unanticipated problems are any event that is: unexpected in nature, frequency or severity; related or 
possibly related to participation in the research; or suggest that the risk of harm to study participant s is 
increased.  
8.2 CLASSIFICATION OF AN  ADVERSE EVENT  
 
8.2.1  ASSESSMENT OF ADVERSE EVENT SEVERITY  
The determination of AE severity rests on medical judgment of a medically qualified investigator. The 
severity of AEs will be graded using the following definitions:  
• Mild : Awareness of sign, symptom, or event, but easily tolerated.  
• Moderate : Discomfort en ough to cause interference with usual activity and may warrant 
intervention. 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  29 • Severe : Incapacitating with inability to do usual activities or significantly affects clinical status 
and warrants intervention.  
8.2.3  EXPECTEDNESS  
 
Any adverse event, the specif icity, nature, or severity of which is not consistent with the underlying 
disease process, will be considered an unexpected AE. AEs that are expected based on the  underlying 
disease process  are worsening renal function, ureteral stricture disease, or obstructed urinary infection.     
 
8.3 TIME PERIOD AND FREQ UENCY FOR EVENT ASSE SSMENT AND FOLLOW -UP 
The site Investigator is responsible for monitoring the safety of participants enrolled into the study at 
the study sites.  Monitoring for AEs and SAEs will occur from informed consent to month 24.  Adverse 
events will be queried as part of periodic email/telephone follow -up with participants. 
8.4 REPORTING PROCEDURES  
 
8.4.1  ADVERSE EVENT REPORT ING  
For this study, non- serious AEs will not be collected on the safety reporting page of the eCRF, but should 
be documented in the source documents and followed according to local standard of care.  Investigators 
are also responsible for promptly reporting AEs to their reviewing IRB in accordance with local 
requirements.  
8.4.2   SERIOUS ADVERSE EVEN TS 
SAEs  occurring from informed consent  to month 24 will be captured on the SAE eCRF .  
8.4.3 SERIOUS ADVERSE EVEN T REPORTING  
All SAEs , whether or not deemed intervention related or expected, must be reported  by the investigator 
or qualified designee within 1 working day of first becoming aware of the event. The investigator or 
qualified designee will enter the required information regarding the SAE into the appropriate module of the eCRF. If the eCRF system is temporarily unavailable, the event, including the investigator -
determined causality to study intervention  should be reported via the back -up paper SAE form to the 
SDRC. Upon return  of the availability of the electronic data capture (EDC) system, the SAE information 
must be entered into the eCRF.  
When additional relevant information ( i.e., final diagnosis, outcome, results of specific investigations, 
etc.)  becomes available, the Investigator will record follow -up information according to the same 
process used for reporting the initial event as described above. The Investigator will follow all reportable events until resolution, stabilization or the event is otherwise explained.  
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  30 The SDRC will follow all SAEs until resolution, until stabilization, until otherwise explained or until the 
last subject completes the final follow -up, whichever occurs first. The SDRC will report all SAEs to the 
Data Safety Monitoring Board (DSMB) chair in acc ordance with the DSMB Charter .  
8.4.4 UNANTICIPATED PROBLEM REPORTING  
AEs that meet the criteria of serious, related to study intervention, and unexpected, qualify for 
expedited reporting to the IRB. The Investigator will assess all SAEs occurring at his/ her clinical center  
and evaluate for “unexpectedness” and relationship to study procedures or intervention. The Investigator is required to complete and submit a r eport for the events identified as serious, study 
procedure or intervention related , and unexpected and submit the report to their reviewing IRB in 
accordance with local requirements.  
A copy of this report should be kept at the clinical center  and also forwarded to the SDRC within the 
same timeline used for reporting to regulatory author ities.  
8.4.5 EVENTS OF SPECIAL IN TEREST  
Episodes of hyponatremia requiring medical attention (e.g., hospitalization) will be reported as a Serious Adverse Event, as described in 8.4.2.  
8.4. 6 REPORTING OF PREGNAN CY  
During the course of the trial, all stu dy participants of childbearing potential will be instructed to contact 
their Investigator immediately if they become pregnant. Pregnancy occurring during the study period, 
although not considered a serious adverse event, must be reported within the same t imelines as a 
Serious Adverse Event. The pregnancy will be recorded on the appropriate pregnancy form  in the EDC 
database . The pregnancy will be followed until final outcome. Any associated AEs or SAEs that occur will 
be recorded in the EDC database . 
8.5 SAFETY OVERSIGHT  
The Investigator is responsible for monitoring the safety of participants enrolled into the study at the ir 
clinical center.  The SDRC will follow all SAEs until resolution, until stabilization, until otherwise 
explained or until the last subject completes the final follow -up, whichever occurs first.  The SDRC will 
report all SAEs to the Data Safety Monitoring Board (DSMB) chair in accordance with the DSMB Charter .  
The DSMB will review detailed safety data approximately every 6 months throughout the study.  
    
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  31 9 CL INICAL MONI TORING 
SDRC  will employ  a “risk -based monitoring” strategy that ensures human subject protection and data 
quality are held in the utmost regard. Data- Driven Trial Management (DDTM) is a targeted analysis –
based surveillance effort designed to proactively minimize risk and improve quality. 
SDRC  focuses on a simple and pragmatic project management strategy based on the following quality by 
design principles with human subject protection and data quality and integrity as the foundation of 
project planning and execution:  1) the correct subjects are enrolled and consented, 2) acceptable 
treatment adherence is met, 3) complete efficacy data is asc ertained, 4) complete safety data is 
ascertained, and 5) good clinical practices (GCP) are followed.  
Integrated SDRC sy stems support  our R BM strat egies allowing  us to closely monitor and track ag reed  
upon k ey risk indicat ors and follow-u p quickly  with  necessary interven tions.  In additi on, our systems 
support  focu sed mon itoring activities, including sou rce data verific ation, onli ne drug accoun tability, and  
regula tory docume nt tracking. 
Based  on our significant data qual ity exp erience,  the SDRC  has established strategies and supporti ng 
tools to deliver high qual ity da ta that is critical f or all  trials including long term, ev ent driven trials.  B y 
integ rating the v aried data sources and providin g seamless reporting of tr ial data status, we enable th e 
team to pro actively manage trials.  
 A s part of a concerted effort to follow the study in a detailed and orderly manner in accordance with 
established principles of GCP and applicable regulations, a SDRC  team member  will maintain frequent 
telephone and written communication. 
 
10 STATISTICAL CONSIDER ATIONS   
 
10.1 STATISTICAL AND ANAL YTICAL PLANS  
The statistical team at SDRC  will perform the statistical analyses described in this section.  An Intention-
to-treat analysi s will be performed and will serve as the primary analysis for the primary objective in this 
study. The Intention- to-treat cohort will include all randomized study participant s. 
In a separate document, a statistical analysis plan (SAP) will be developed by  the SDRC  team to include a 
comprehensive description of the statistical methods and analyses for the primary manuscript as well as 
the final study report. Prior to analysis, study population details, including the number of sites, the 
number of study part icipants  in each study arm, and the number of study participant s lost to follow -up 
will be described. Data for all randomized study participants, whether or not they completed all protocol requirements, will be included for analysis.  
 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  32 10.2 STATISTICAL HYPOTHESES  
The primary hypothesis of the time -to-first symptomatic stone will be tested under Cox p roportional 
hazards model as:  
H0: HR= 1.0  𝑣𝑣𝑣𝑣. H𝑎𝑎:  HR # 1.0  
Other hypothese s of interest that the intervention will increase fluid intake (goal urine output at least 
2.5 L daily) will lead to a fewer symptomatic and asymptomatic stone events over 2 years of study 
period.   In addition, we will test time -to-recurrent symptomatic stone events.  
10.3 ANALYSIS DATASETS  
Data from all randomized study participants, regardless of whether or not they completed all protocol 
follow- up requirements, will be included for analysis.  The analysis population will be the intent -to-treat 
(ITT) population.  In addition,  a per -protocol analysis will be performed.  The analysis population for the 
per protocol analysis will consist  of partcipants in the ITT population  except those who have had a 
major protocol de viation.  
10.4 DESCRIPTION OF STATISTICAL METHODS  
 
10.4.1  GENERAL APPROACH  
The primary analysis will be conducted by intention- to-treat principles. The analysis cohort for this study 
consists of all randomized study participant s regardless of whether the st udy participant  received the 
randomly assigned intervention strategy. All study participants who provide informed consent and who 
are randomized will be included in the analyses. For those study participant s who are lost to follow -up, 
or who drop out of th e study , the analyses will include all data up to the point of their last data 
collection whenever applicable. Safety data will be collected on all randomized study participant s. All 
statistical analysis will be tested at two -sided nominal significance lev el of 0.05.   If missing data 
constitute <2% of observations, the analysis will utilize single imputation (mean for continuous variables, 
mode for categorical variables).  If missing data are >2% of observations, then the approach to missing 
data will depen d on checks of the missing- at-random assumption, and will be detailed in the Statistical 
Analysis Plan.   
10.4.2  ANALYSIS OF THE PRIM ARY EFFICACY ENDPOIN T(S)  
The primary endpoint (symptomatic stone event) will be analyzed as a time -to-event outcome with a 
log-rank test42 or equivalently, the Cox proportional hazards model ,43 the approach used for calculating 
sample size requirements . Kaplan -Meier estimates44 of cumulative event rates as a function of follow -up 
time will calculated and displayed.  In addition, stratified Cox proportional hazards model will be 
conducted wher e the strata are those used in the randomization scheme. Furthermore, data collected 
on subsequent recurrent events of symptomatic stone will be analyzed using the Andersen- Gill model45 
(with adjust ment  for correlation within a study participant) and/or negative binomial regression.    
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  33 A symptomatic stone event will be defined as  stone passage, symptomatic stone requiring procedural 
intervention, or any asymptomatic stone undergoing procedural intervention.  A pre -specified  
sensitivity analysis  of the definition of symptomatic stone event  will include stone passage, symptomatic 
stones requiring procedural intervention, and asymptomatic stones undergoing procedural intervention 
that meet at least one of  the following criteria: stone size  at least 4 mm in any dimension, mobile stone, 
hematuria or recurrent urinary tract infection.   An additional pre -specified sensitivity analysis will 
exclude any symptomatic stone events that occur within 30 days of randomiza tion.    
10.4.3  ANALYSIS OF THE SECO NDARY ENDPOINT(S)  
Secondary endpoints will include a composite outcome of symptomatic stone event, asymptomatic 
stone formation, or stone growth assessed at study conclusion.  These outcomes will be analyzed  using a 
logistic regression model, since asymptomatic stone formation or stone growth are subject to interval 
censoring (the exact occurrence time will be unknown) . 
24 hour urine total volume  and lower urinary tract symptoms (as measured by CASUS)  will be compared  
between intervention and control arms  using t -test or Wilcoxon rank -sum test, based on the assumption 
of normality of the data.     
10.4.4  SAFETY ANALYSES  
Proportion of study participants developing symptomatic hyponatremia will be compared in the intervention and control arms using the Pearson’s chi square test  or Fisher’s exact test, as appropriate . 
10.4.5  ADHERENCE  AND RETENTION ANALY SES 
24-hour urine total volumes will be the main adherence outcome.   
10.4.6  BASELINE DESCRIPTIVE  STATISTICS  
Base line descriptive characteristics will include demographic (age, race/ethnicity, sex), socioeconomic 
status, body mass index,  stone former status (first time vs recurrent), baseline medication use,  and 24-
hour urine volume at study entry.  Baseline characte ristics will be summarized as mean (standard 
deviation), median (25th, 75th percentiles), min and max.  
10.4.7  PLANNED INTERIM ANAL YSES  
Interim efficacy analyses are not planned.  However, the study leadership will monitor the data integrity 
and sample size assumptions while the study is ongoing at two time points: 1) when approximat ely 1/3 
of the study participant s are enrolled or 12 months  after the 1st study participant  enrolled , whichever 
occurs first; and 2) when about 2/3 of the study participant s are enrolled or 20  months  after the 1st 
study participant  enrolled , whichever occurs first.   
The event rate and dropout rate will be monitored in an aggregated fashion ( ie, blinded  to the 
intervention  allocation).  If the event rate is lower than anticipa ted, or if dropouts exceed the assumed 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  34 rate, then the target enrollment might  be increased to maintain sufficient power  to complete the study.  
In addition, if study enrollment is slower than expected, additional recruitment sites may be identified. 
The fi delity of SPS will be assessed in two ways.  First, health c oaches and participants will complete 
separate checklists noting which elements of SPS were addressed during the session(s).  Second, a  15% 
random sample of SPS sessions will be audio or video  recorded and assessed by independent reviewers 
for adherence to the specified elements of SPS.   
10.4.7.1  DATA AND SAFETY MONI TORING REVIEW  
A Data and Safety Monitoring Board (DSMB) will be appointed by the NIDDK to monitor study participant  
safety and to  review performance of the protocol. A DSMB C harter that outlines the operating guidelines 
for the committee and the procedures for the interim evaluations of study data will be developed by the 
NIDDK and agreed upon at the initial meeting of the DSMB. Reports will be prepared regularly by the SDRC  
as requested by the DSMB chair. Depending upon the operational plan established by the DSMB, the report might include recruitment and retention rates, interim analyses, primary and secondary endpoints, SPS fideli ty, adherence,  and other information as requested by the committee. After each meeting, the 
DSMB will make recommendations to the NIDDK and the trial leadership about the continuation of the study. 
 
10.4.8  ADDITIONAL SU B-GROUP ANALYSES  
Subgroup analyses will be performed for the primary outcome among the ITT population in order to explore whether intervention on symptomatic kidney stone are consistent across subgroups. The same subgroup analyses will also be repeated in the per -protocol population. Subgroups of interest would be 
clinical centers , sex, race, age (adult/adolescent), baseline medical treatment for USD prevention  and 
first time/recurrent stone former.   An SPS treatment fidelity subgroup analysis may be conducted, if 
sufficien t variability in fidelity exists.  Subgroup analyses will be summarized in a forest plot which will 
include the interaction p- values.   
10.4.9 MULTIPLE COMPARISON/ MULTIPLICITY  
A single primary outcome is specified, therefore no adjustment for multiple prim ary endpoint 
comparisons will be necessary.  Secondary outcome comparisons will not be adjusted for multiple 
testing.  
10.4.10 ECONOMIC A NALYSIS  
In accordance with expert recommendations, the economic evaluation will be performed using the 
societal perspective.46  Using data already being collected during the trial, the following economic model 
inputs will be estimated: (1) resources required to provide the study interventions; (2) patient time and (3) medical resource use. To estimate study intervention costs, we will use a tool specifically designed to 
estimate costs associated with patient- centered interventions (R01NR011873).
47 The costs of medical 
resource use will be assigned based on payment schedules (e.g., Medicare). To incorporate potential 
differences in health -related quality of life experienced by participants in the cost -effectiveness analysis, 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  35 health state utilities will be estimated from existing literature.48 Full details of the economic analysis will 
be specified in the Economic Statistical Analysis Plan.  Cost effectiveness analyses will use estimates of 
incremental cost effectiveness ratios (ICER).   
10.5 SAMPLE SIZE  
Conservative power calculations are based on symptomatic recurrence rates reported by Rule and 
colleagues.49 The following assumptions are  incorporated into the power calculation:  
1) Unit of randomization: patient  
2) Equal randomization ratio (1:1)  
3) 15% event rate (composite of USD recurrence) over 2 years in control arm  
4) 30% relative risk reduction for intervention arm (HR = 0.7)  
5) 20% attrition rate  (dropouts, loss to follow up)  
6) Two -sided alpha of 0.05, log- rank test for time to event  
7) 2 year follow up 
N = 821 per arm (total = 1642 study participants) provides 80% power to detect the pre -specified 
relative risk .  Sample size calculations were carried out using SAS (PROC POWER) version 9.4 (SAS 
Institute Inc., Cary, NC).  
Study participants will be recruited from the 4 Clinical Centers over a 2- year period.  
 

PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  36 10.6 MEASURES TO MINIMIZE  BIAS  
 
10.6.1  ENROLLMENT/ RANDOMIZ ATION/ MASKING PROCEDURES  
Potentiall y eligible  study participants will be identified and screened by interview. Interested study 
participant s will be asked to give informed consent and undergo a screening evaluation to include a 
complete history, physical examination, and laboratory tests. Females of childbearing potential will 
undergo pregnancy testing to rule out pregnancy at baseline. Study  personnel will assess each study 
participant  against each inclusion and each exclusion criterion, and the I nvestigator  (or designated 
physician sub- investigator)  will determine the study participant’s eligibility for study participation. The 
informed consent process and all assessments will be documented in the study participant ’s medical 
record or comparable source document. 
10.6.2  EVALUATION OF SUCCESS OF BLINDING  
Data that may potentially unblind treatment assignment will be handled with special care, so that before 
unblinding, such data will only be available to :  
• SDRC staff who require this data for monitoring, data management and statisicial  activities, and 
safety surveillance  
• The clinical center study coordinators who will randomize and interact with both intervention 
and control arm participants  
• The SPS health coaches, who will interact with intervention arm participants who are not meeting their fluid intake goals (see 6.1.3)  
Procedures for unblinding an Investigator  and/or a participant are included in the study Manual of 
Procedures and the Statiscial Analysis Plan.  
 
11 SOURCE DOCUMENTS AN D ACCESS TO SOURCE D ATA/DOCUMENTS  
Source documents include all recordings of observations or notations of clinical activities and all reports 
and records necessary for the evaluation and reconstruction of the clinical study. Accordingly, source documents include, but are not limited to, laboratory reports , radiologist reports  and scan images , 
ultrasound photographs, study participant  progress notes, hospital charts, pharmacy records, and any 
other similar reports or records of any procedure performed in accordance with the protocol.  
Whenever possible, the original recording of an observation should be retained as the source document; 
however, a photocopy is acceptable provided that it is a clear, legible, and exact duplication of the 
original document. 
Regulations require that investigators maintain information in the study participant ’s research records 
that corroborate data collected on the eCRF. In order to comply with these regulatory requirements, the 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  37 following information will be maintained and made available as required by SDRC  monitors and/or 
regulatory inspectors:  
1. Medical history/physical condition of the study participant  before involvement in the study 
sufficient to verify protocol entry criteria.  
2. Medical record documenting that informed consent was obtained for the study participant ’s 
participation in the study.  
3. Dated and signed notes for each in -person study participant  visit, including results of 
examinations.  
4. Notations on abnormal laboratory results. 
5. Dated printouts or reports of special assessments (eg, 24- hour urine collections ). 
6. Description of adverse events (AEs) and follow -up of the AEs (minimally, event descripti on, 
severity, onset date, duration, relation to study drug/device, outcome, and treatment for 
AE). 
7. Notes regarding concomitant medications taken during the study (including start and stop dates).  
8. Study participant’s condition upon completion of or withdrawal from the study.  
 
12 QUALITY ASSURANCE AN D QUALITY CONTROL  
NIDDK  and their representatives (e.g.  SDRC) agree to be responsible for implementing and maintaining 
quality control and quality assurance systems to ensure that all work incidental to this prot ocol is 
conducted and data are generated, documented, and reported in compliance with the protocol; 
accepted standards of Good Clinical Practice (GCP); and all applicable federal, state, and local laws, rules 
and regulations relating to the conduct of the clinical study. 
The clinical center I nvestigator will provide current copies of the study protocol to all subinvestigators or 
other site personnel responsible for study conduct.  
The SDRC PI will provide the NIDDK with copies of all institutional review boa rd (IRB) actions regarding 
the study.  
 
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
 
13.1 ETHICAL STANDARD  
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  38 Research will be conducted in compliance with regulations as outlined in 45 CFR part 46 and the ethical 
framework in the Belmont Report.  
13.2 INSTITUTIONAL REVIEW BOARD  
The appropriate IRB must approve the protocol and informed consent documents, agree to monitor the 
conduct of the study, and agree to review study progress periodically, at intervals not to exceed 1 year. 
The investigator will p rovide SDRC  with documentation that the IRB/EC has approved the study before 
the study may begin. 
In addition, the I nvestigator must provide the following documentation to NIDDK  or their 
representative (e.g. , SDRC) : 
1. IRB annual reapproval of the protocol, per current regulations and current International 
Conference on Harmonisation guidelines.  
2. IRB approval of revisions to the informed consent documents or any amendments to the 
protocol . The investigator will provide th e NIDDK  or their representative with documentation 
of all approvals.  
 
13.3 INFORMED CONSENT PRO CESS  
 
13.3.1 CONSENT PROCEDURES AND DOCUMENTATION  
The clinical center I nvestigator  has both ethical and legal responsibility to ensure that each study 
participant  being considered for inclusion in this study is given a full explanation of the study. I nformed 
consent will be obtained from all study participants (or their guardian or legally authorized 
representative [LAR]) before any study -related procedures (including any pretreatment procedures, 
such as preprocedure sedation) are performed or given.  
Informed consent will be documented on an informed consent form (ICF), or through a remote consent 
process,  that has been approved by the same IRB/EC responsible for approval of this protocol. The ICF 
will conform to FDA regulations in 21 CFR Part 50 and to the institutional requirements for informed 
consent and applicable regulations. The I nvestigator agrees to obtain approval from SDRC  of any ICF 
intended for use in the study, before submission for IRB approval.  
Consent will be obtained from the participant if age ≥18 years or parent/guardian consent if age < 18 
years with adolescent assent,  after all questions about study procedures have been addressed .  
In addition, age -appropriate assent will be obtained from the pediatric study participant s themselves. 
Informed consent is an ongoing process that takes place between the I nvestigator/study staff and study 
participants. In most cases, this process is initiated with informed consent at the start of the study; however, it also takes place as an ongoing dialogue between the I nvestigator/study staff and study 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  39 participant s during the entire duration of their participation. Should the study participant s become 
intolerant of any aspect of the study, their participation will be discontinued. 
The approved consent process will be completed with the prospective study study participant  or his or 
her LAR, and the I nvestigator or qualified designee will be available to answer questions regarding 
procedures, risks, and alternatives.  
 
13.4  PARTICIPANT AND D ATA CONFIDENTIALITY  
To minimize the chance for serious and unexpected adverse events, study participants will be screened 
through exclusion criteria for any health conditions that may be exacerbated by participating in this 
study. Participants are given guidance on when to seek medical attention and a reporting protocol is in 
place to capture any changes in symptoms with study participation.  
A potential risk of this study is a breach of participant confidentiality. We will minimize this risk by linking individual identifying information with participant ID numbers at the site  that will only be 
accessed by the study team in the case of an adverse medical event, participant dropout, or if otherwise 
deemed necessary by the Investigator s.  
Due to the financial incentives in this study, we will be collecting S ocial Security numbers from adult 
participants so that we can complete W -9 forms for them . Social S ecurity numbers only will be used to 
generate W -9 forms and will be deleted once they are no longer needed.   All adult participa nts will be 
asked provide informed consent for use of S ocial Security numbers for this purpose. We will also collect 
home addresses to mail incentive payments. Incentive payments will be managed throu gh a University 
of Pennsylvania -approved partnership bet ween Way to Health and Wells Fargo. Accidental disclosure of 
Social Security numbers could lead to identity theft. We will use commercial -grade encryption to protect 
Social Security information in transit. Names and addresses will be stored in encrypted da tabases. These 
data will be viewable only by the respective participants , the CC study coordinator s, and staff at Way to 
Health and Wells Fargo .  
Adolescent participants will be paid via Clin Card, according to the procedures of their clinical center’s 
institution. Social Security numbers will not be collected in the Way to Health system for adolescents, 
and their information will not be shared with Wells Fargo.  
Paper -based records will be kept in a secure location and only be accessible to personnel involved in the 
study. Computer -based files will only be made available to personnel involved in the study through the 
use of access privileges and passwords. Wherever feasible, identifiers will be removed from study -
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  40 related information. Precautions are in plac e to ensure the data are secure by using passwords and 
encryption, because the research involves web- based surveys.  
Research material will be obtained from patient charts, participant surveys, and from the smart  water  
bottle .  All participants will provide  informed consent for access to these materials. The data to be 
collected include demographic data (e.g., age, sex, self -identified race), outcome data, and daily water 
intake  data collected by the smart water bottle .  Research material that is obtained wi ll be used for 
research purposes only. The same procedure used for the analysis of automated data sources to ensure 
protection of patient information will be used for the survey data, in that patient identifiers will be used 
only for linkage purposes or to  contact study participants . The study identification number, and no other 
identifying information, will be used on all data collection instruments. All study staff will be reminded 
to appreciate the confidential nature of the data collected and contained in these databases.  
Partic ipation in the proposed study is completely voluntary. The research team will institute strict 
procedures to maintain confidentiality. All data and records generated during this study will be kept 
confidential and in accordance with institutional policies and HIPAA on study participant  privacy. Study 
participant s will be assigned a unique participant ID number, as mentioned above.  The study data will 
only be shared with the investigative team during the implementation of the study and results will only be presented in aggregate form. Further, study participant s and families will have direct access to the 
study team as a means to voice any questions, concerns, or reservations. Contact information will be 
provided at the time of consent. Should any specific c oncerns arise, the study team will intervene to 
address problems including, if needed, a change or discontinuation of study procedures. The IRB of the appropriate USDRN CC  will promptly be informed of any concerns.  
The following entities, besides the membe rs of the research team, may receive protected health 
information (PHI) for this research study: a) Wells Fargo, the company which processes study -related 
payments. Patient addresses and account balances will be stored on their secure computers. b) P’unk Ave., LLC, a software development company designing the Way to Health website. P’unk Ave. will not 
store any of the study participants ' PHI, but they will have access to de -identified patient information, 
for the purposes of website administration and devel opment. c) Hidrate Spark, t he manufacturer of the 
smart water bottle that will be used  in the study.  d) Twilio, Inc., the company which processes some 
study- related messages. Twilio will store study participants ' phone numbers on their secure computers. 
e) the SDRC which manages the EDC database and performs study management and monitoring. f)  IBM 
Clinical which hosts the EDC database server. g) the central laboratory at University of Texas 
Southwestern, which performs the 24- hour urine testing. h) t he Institutional Review Boards and offices 
for Human Research Protections at the SDRC and each Clinical Center . i) Federal and state agencies (for 
example, the Department of Health and Human Services, the National Institutes of Health, and/or the 
Office for Human  Research Protections), or other domestic or foreign government bodies if required by 
law and/or necessary for oversight purposes. 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  41 13.4.1 RESEARCH USE OF S TORED HUMAN SAMPLES,  SPECIMENS OR D ATA  
The research use of stored identified or coded specimens or data, when researchers can identify the 
sources, must receive prospective and continuing IRB review and approval. This includes research protocols where the remaining research activities are lim ited to data analyses, and the subsequent 
research use of specim ens or data previously collected under now -terminated protocols. 
13.5 FUTURE USE OF STORED  SPECIMENS  
 
Specific consent is required for biological samples to be stored for future studies . Study participant s who 
consent to such storage of samples will be asked to follow the site’s IRB -approved process  to document 
their consent. Participation in the study is not contingent upon a study participant’s agreement to provide 
additional biological samples.  
Once the  appropriate essential information has been provided to the study participant  and fully explained 
by the investigators or qualified designee, and it is felt that the study participant  understands the 
implications of participating, the study participant  and the investigator or designee will sign and date the 
institutional review board (IRB)/ethics committee (EC) -approved written ICF  or complete the IRB -
approved remote consent process . If a paper ICF was signed, t he study participant  will receive a copy of 
the signed ICF ; the original signed and dated ICF will be kept in the site’s regulatory file. Documentation 
of the study participant’s informed consent for and participation in this trial will be noted in the study 
participant ’s medical record.  
The study pa rticipant  or his or her LAR will be informed in a timely manner if new information becomes 
available that may be relevant to the study participant’s willingness to continue participation in the trial. The communication of this information to the study part icipant  will be documented.  
14 DATA HANDLING AND RE CORD KEEPING  
 
14.1 DATA COLLECTION AND MANAGEMENT RESPONSIB ILITIES  
Study sites will transcribe study participant  source data, or directly enter required data,  into eCRFs using 
a computerized electronic data capture (EDC) system. The EDC system is managed by the SDRC, and is compliant with all relevant aspects of GCP. Edit checks, electronic queries, and audit trails are built into 
the system to ensure accurate and complete data collection.  
Protocol- specified source documents (eg, hospital discharge summaries, operative/procedural reports, 
and other source documents, as applicable ) will be retrieved as necessary. Copies of all study -related 
documentation will be  retained at the site.  
Periodic data quality checks will be performed to ensure appropriate data recording. The database will 
be restricted to only authorized users and will be password- protected. Individual user accounts with 
passwords will be used to restrict access. A network firewall will be used to prevent unauthorized 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  42 external use. Data will be stored on encrypted, password- protected servers and backed up regularly 
through the SDRC, located at Duke Clinical Research Institute . 
 
14.2 STUDY RECORDS RETE NTION  
The clinical center Investigator  will maintain the records of final eCRFs, worksheets, and all other study-
specific documentation (eg, source documentation) until notified by the NIDDK or SDRC  that records 
may be destroyed. To avoid error, the I nvestigator will contact the SDRC  before the destruction of any 
records pertaining to the study to ensure they no longer need to be retained. In addition, SDRC  will be 
contacted if the PI plans to leave the institution so that arrangements can be made for the transfer of 
records.  
The I nvestigator  will not dispose of any records relevant to this study without either (1)  obtaining 
written permission from the NIDDK  or (2) providing an opportunity for the NIDDK  to collect such 
records. The I nvestigator  takes responsibility for maintaining adequate and accurate source documents 
of all observations and data generated during this study. Such documentation is open  to inspection by 
the sponsor, their representatives,  as well as the NIH, and other regulatory agencies,  as provided by law.  
 
14.3 PROTOCOL DEVIATIONS  
A protocol deviation is defined as an event where the I nvestigator or site personnel did not conduct the 
study according to the investigational plan or the Investigator Agreement.  
Investigators are required t o obtain approval from the SDRC PI or their designated delegate, and their 
IRB, before initiating deviations from the investigational plan or protocol, except where necessary to 
protect the life or physical well- being of a study participant  in an emergency. Such approval will be 
documented in writing and maintained in study files. Preapproval is generally not expected in situations 
where unforeseen circumstances are beyond the investigator’s control, (eg, study participant  did not 
attend scheduled follow -up visit, blood sample lost by laboratory); however, the event is still considered 
a deviation.  
Deviations will be reported to SDRC  regardless of whether medically justifiable, or taken to protect the 
study participant  in an emergency. See th e Manual of Procedures for detailed information on reporting 
deviations.  
The IRB/EC will be informed of all protocol changes by the sponsor or the investigator in accordance 
with applicable regulations and the IRB/EC’s established procedures. No deviations from the protocol of any type will be made without complying with all the IRB/EC’s established procedures.  
Investigators will maintain documentation of the dates and reasons for each deviation from the protocol. 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  43  
14.4 PUBLICATION AND DAT A SHARING POLICY  
The USDRN will be  operating under the NIDDK Data Sharing Policy.  
(https://www.niddk.nih.gov/research-f unding/process/human- subjects -
research/Documents/PublicversionNIDDKdatasharingpolicy2013July2013.pdf ).  This policy seeks 
maximal benefit from the data and samples collected from multi -center clinical studies in which the 
NIDDK has invested substantial resources, and study investigators and participants have invested 
substantial effort. NIDDK has established repositories for study data, and biologic and genetic samples to foster the use of these resources. The policy was established to balance the interest of the study investigators with those of the larger scientific research community by setting a defined period of exclusive access by study investigators; after that time data will become “publicly” available through the 
NIDDK Data Repository. 
 
15 CONFLICT OF INTEREST POLICY  
A USDRN financial disclosure guideline has been developed to promote fair, open, and unfettered 
discussion of important conflict of interest concerns that often emerge during the design and conduct of 
multicenter clinical trials. The aim is to ensure that the scientific design, conduct, and reporting of the 
study are not biased by financial influences. The USDRN guideline does not supersede Institutional 
requirements developed to comply with Public Health Service (PHS) regulations on Financial Conflict of 
Interest reporting. This guideline requires Principal Investigators and other active participants in study 
design and conduct, such as committee members, subcontractors, or other regular attendees at 
Steering Committee meetings to fully disclose all commercial or professional ties that might pose a real 
or perceived conflict of interest. Oversight of reported conflict disclosures will be managed by the 
Executive Committee.  
16  LITERATURE REFEREN CES  
1. Scales CD, Jr., Smith AC, Hanley JM, Saigal CS. Prevalence of Kidney Stones in the United States. 
Eur Urol 2012.  
2. Litwin MS, Saigal C. Urologic Diseases in America. In: Services UDoHaH, ed. Washington, DC: US 
Government Printing Office; 2012.  
3. Fwu CW, Eggers PW, Kimmel PL, Kusek JW, Kirka li Z. Emergency department visits, use of 
imaging, and drugs for urolithiasis have increased in the United States. Kidney Int 2013;83:479- 86. 
4. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and 
recurrences in idiop athic calcium nephrolithiasis: a 5 -year randomized prospective study. J Urol 
1996;155:839- 43. 
5. Lotan Y, Buendia Jimenez I, Lenoir -Wijnkoop I, et al. Increased water intake as a prevention 
strategy for recurrent urolithiasis: major impact of compliance on cost-effectiveness. J Urol 
2013;189:935- 9. 
6. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other 
nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993;328:833 -8. 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  44 7. Frank M, De Vries A. Preventio n of urolithiasis. Education to adequate fluid intake in a new town 
situated in the Judean Desert Mountains. Arch Environ Health 1966;13:625- 30. 
8. Parks JH, Goldfischer ER, Coe FL. Changes in urine volume accomplished by physicians treating 
nephrolithiasi s. J Urol 2003;169:863- 6. 
9. Jackson E. Between a Rock and a Hard Place: Getting Families to Change Behaviors to Reduce 
Pediatric Stone Disease Recurrence. J Urol 2014;192:1324- 5. 
10. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA 
guideline. J Urol 2014;192:316- 24. 
11. Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD, Clinical Guidelines Committee of the 
American College of P. Dietary and pharmacologic management to prevent recurrent nephrolithiasis in 
adults: a cli nical practice guideline from the American College of Physicians. Ann Intern Med 
2014;161:659- 67. 
12. Volpp KG, Gurmankin Levy A, Asch DA, et al. A randomized controlled trial of financial incentives 
for smoking cessation. Cancer Epidemiol Biomarkers Prev 2006;15:12- 8. 
13. Volpp KG, Troxel AB, Pauly MV, et al. A randomized, controlled trial of financial incentives for 
smoking cessation. N Engl J Med 2009;360:699- 709.  
14. Halpern SD, French B, Small DS, et al. Randomized trial of four financial -incentive pro grams for 
smoking cessation. N Engl J Med 2015;372:2108- 17. 
15. Higgins ST, Bernstein IM, Washio Y, et al. Effects of smoking cessation with voucher -based 
contingency management on birth outcomes. Addiction 2010;105:2023- 30. 
16. Volpp KG, John LK, Troxel A B, Norton L, Fassbender J, Loewenstein G. Financial incentive -based 
approaches for weight loss: a randomized trial. JAMA 2008;300:2631 -7. 
17. John LK, Loewenstein G, Troxel AB, Norton L, Fassbender JE, Volpp KG. Financial incentives for 
extended weight los s: a randomized, controlled trial. J Gen Intern Med 2011;26:621- 6. 
18. Forster JL, Jeffery RW, Sullivan S, Snell MK. A work -site weight control program using financial 
incentives collected through payroll deduction. J Occup Med 1985;27:804- 8. 
19. Jeffery R W, Forster JL, Snell MK. Promoting weight control at the worksite: a pilot program of 
self-motivation using payroll -based incentives. Prev Med 1985;14:187- 94. 
20. Vandrey R, Bigelow GE, Stitzer ML. Contingency management in cocaine abusers: a dose -effect 
comparison of goods -based versus cash -based incentives. Exp Clin Psychopharmacol 2007;15:338- 43. 
21. Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ. Incentives improve outcome 
in outpatient behavioral treatment of cocaine dependence. Arch G en Psychiatry 1994;51:568- 76. 
22. Silverman K, Wong CJ, Higgins ST, et al. Increasing opiate abstinence through voucher -based 
reinforcement therapy. Drug Alcohol Depend 1996;41:157- 65. 
23. Volpp KG, Loewenstein G, Troxel AB, et al. A test of financial ince ntives to improve warfarin 
adherence. BMC Health Serv Res 2008;8:272.  
24. Kimmel SE, Troxel AB, Loewenstein G, et al. Randomized trial of lottery -based incentives to 
improve warfarin adherence. Am Heart J 2012;164:268 -74. 
25. Priebe S, Bremner SA, Lauber C, Henderson C, Burns T. Financial incentives to improve 
adherence to antipsychotic maintenance medication in non- adherent patients: a cluster randomised 
controlled trial. Health Technol Assess 2016;20:1- 122.  
26. Skinner BF. Cumulative Record: A selection of papers. 3rd ed. New York: Meredith; 1972. 
27. Bigelow GE, Silverman K. Theoretical and Empirical Foundations of Contingency Management 
Treatments for Drug Abuse. In: Higgins ST, Silverman K, eds. Motivating Behavior Change Among Illicit 
Drug Users. Washington, DC: American Psychological Association; 1999:15- 30. 
28. Sorsdahl K, Myers B, Ward CL, et al. Adapting a blended motivational interviewing and problem -
solving intervention to address risky substance use amongst South Africans. Psychother Res 
2015;25:435 -44. 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  45 29. Hill-Briggs F, Gemmell L. Problem solving in diabetes self -management and control: a systematic 
review of the literature. Diabetes Educ 2007;33:1032- 50; discussion 51- 2. 
30. Gross R, Bellamy SL, Chapman J, et al. Managed problem solving for antiretroviral therapy 
adherence: a randomized trial. JAMA Intern Med 2013;173:300- 6. 
31. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic 
hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative 
Research Group. JAMA 1991;265:3255- 64. 
32. Seekles W, van Straten A, Beekman A, van Marwijk H, Cuijpers P. Stepped care for depression 
and anxiety: from primary care to specialized mental health care: a randomised controlle d trial testing 
the effectiveness of a stepped care program among primary care patients with mood or anxiety disorders. BMC Health Serv Res 2009;9:90.  
33. Saint S, Greene MT, Krein SL, et al. A Program to Prevent Catheter -Associated Urinary Tract 
Infection  in Acute Care. N Engl J Med 2016;374:2111- 9. 
34. Sarica K, Inal Y, Erturhan S, Yagci F. The effect of calcium channel blockers on stone regrowth 
and recurrence after shock wave lithotripsy. Urol Res 2006;34:184- 9. 
35. Fink HA, Akornor JW, Garimella PS, et  al. Diet, fluid, or supplements for secondary prevention of 
nephrolithiasis: a systematic review and meta -analysis of randomized trials. Eur Urol 2009;56:72- 80. 
36. Loewenstein G, Brennan T, Volpp KG. Asymmetric paternalism to improve health behaviors. 
Jama 2007;298:2415- 7. 
37. Loewenstein G, Asch DA, Volpp KG. Behavioral economics holds potential to deliver better 
results for patients, insurers, and employers. Health Aff (Millwood) 2013;32:1244- 50. 
38. Zeelenberg M, Beattie J, van der Pligt J, de Vries N.  Consequences of regret aversion: Effects of 
expected feedback on risky decision making. Organizational Behavior & Human Decision Processes 
1996;65:148- 58. 
39. Zeelenberg M, Pieters R. Consequences of regret aversion in real life: The case of the Dutch 
postcode lottery. Organizational Behavior & Human Decision Processes 2004;93:155 -  68. 
40. Chapman GB, Coups EJ. Emotions and preventive health behavior: worry, regret, and influenza 
vaccination. Health Psychol 2006;25:82 -90. 
41. Patel MS, Asch DA, Volpp KG. Use of wearable monitoring devices to change health behavior --
reply. JAMA 2015;313:1865- 6. 
42. Kalbfleisch JD, Prentice RL. The statistical Analysis of Time Failure Data. 2nd ed. New York, NY: 
John Wiley & Sons; 2002.  
43. Cox D. Regression models and life -tables (with discussion). J Royal Statist Soc B 1972;1972:187-
220. 
44. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn 
1958:457- 81. 
45. Anderson PK, Gill RD. Cox's regression model for counting processes: a larg e sample study. 
Annals of Statistics 1982;10:1100- 20. 
46. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost -Effectiveness in Health and Medicine. New 
York: Oxford University Press; 1996.  
47. Reed SD, Li Y, Kamble S, et al. Introduction of the Tools for Ec onomic Analysis of Patient 
Management Interventions in Heart Failure Costing Tool: a user -friendly spreadsheet program to 
estimate costs of providing patient -centered interventions. Circ Cardiovasc Qual Outcomes 2012;5:113-
9. 
48. Fann C, Huang P, Yen AM, C hen H. Patient Utility Measurement for Managing Ureteral Stones: A 
Modified Standard Gamble Approach. Value Health Regional Issues 2012;1:87- 92. 
49. Rule AD, Lieske JC, Li X, Melton LJ, 3rd, Krambeck AE, Bergstralh EJ. The ROKS nomogram for 
predicting a se cond symptomatic stone episode. J Am Soc Nephrol 2014;25:2878- 86. 
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  46   
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  47 APPENDIX  
Comprehensive Assessment of Self -Reported Urinary Symptoms  
 
 
 
  
PUSH  Version 5.0 
Protocol USDRN01  04 February  2020  
  48  